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ABSTRACT

Bordetella pertussis is the causative agent of whooping cough, a severe disease of
infants characterised by repeated bouts of paroxysmal coughing. Pertussis toxin (PT) is
a major virulence factor of B. pertussis and is a typical A/B bacterial toxin consisting of
five subunits S1-S5 in a ratio of 1:1:1:2:1. The PT subunit genes are organised into an
operon which is not expressed in Escherichia coli, thus hampering the use of this
organism for vaccine production. In this research the five PT subunits were
individually expressed in E. coli by replacing the wild-type transcriptional and
translational signals, and in the case of the S4 subunit the leader peptide has been
exchanged with a modified E. coli 8-lactamase leader sequence. In E. coli CAG629 all
five PT subunits were at least partially processed, with S5 being completely processed.
A stepwise cloning method has then been developed to construct a synthetic PT operon
which simultaneously expresses the five PT subunits in E. coli. Western blot analysis
indicated that in E. coli KS476 containing the synthetic PT operon, S4 and S5 were
completely processed, SI was partially processed, whilst the majority of S2 and S3
remained unprocessed. Periplasmic extracts contained soluble SI and S3; however the
processed form of S2, S4 and S5 were not detected, suggesting that these subunits may
be membrane associated or in an insoluble form. This work should allow an
investigation of the potential of E. coli to produce detoxified PT in a background free of
other pertussis virulence factors that may contribute to the side effects of some vaccine
preparations presently in use. Current vaccines against whooping cough are
administered parenterally, and generate a systemic immune response. An alternative to
this approach is to stimulate mucosal and systemic immune responses by oral
immunisation with live vaccine strains of Salmonella spp. In this research, the five PT
subunits have been individually expressed in Salmonella spp. and the synthetic PT
operon (pDP16) has then been expressed in attenuated aroA mutants of S.
typhimurium, SL3261 and SL7207, via the use of a temperature inducible expression
system. In SL3261 containing individual subunit expression plasmids the S5 subunit

was found to be completely processed, while all other subunits were partially
processed. In SL3261 (pDP16) and SL7207 (pDP16) S5 was completely processed,
SI was partially processed, whilst S2, S3 and S4 remained unprocessed. Induction of
the heat inducible synthetic PT operon at 39.5°C decreased the growth and in vitro
invasiveness of SL3261 and SL7207, compared to uninduced (30°C) and partially
induced (37°C) bacterial cells. Antibody responses were monitered following oral
immunisation of BALB/c mice with the live vaccine strain SL7207 (pDP16) induced at
39.5°C for 1 h. Mice orally immunised with SL7207 (pDP16) primarily produced a
systemic antibody response which recognised the S 1 subunit of PT. The protectiveness
of this vaccine strain was assessed in a mouse intracerebral challenge assay. Mice
immunised with one dose of S. typhimurium SL7207 (pDP16) were not protected
following intracerebral challenge with live B. pertussis. Future work will be aimed at
improving the processing of PT subunits and immunogenicity of this vaccine strain,
using chaperone proteins and in vivo promoters.
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1.

INTRODUCTION

1.1

Whooping Cough

Bordetella pertussis is the causative agent of whooping cough, a particularly severe
and contagious respiratory disease of infants, characterised by repeated bouts of
paroxysmal coughing. This bacterium colonises the respiratory mucosa, having a
specificity for ciliated cells. Colonisation of these cells ultimately results in their
death due to production of toxic compounds by the bacteria. The inability to culture
the organisms during the most severe stage of the disease has led to the assumption
that the disease is mainly toxin mediated (Pittman, 1979).

1.2

Pertussis Vaccines

The incidence of whooping cough has been largely reduced by mass immunisation
with a heat-killed whole cell vaccine routinely administered in combination with
diphtheria and tetanus toxoids. Whole cell vaccines are manufactured in numerous
countries, and although the basic preparation procedures are similar, the vaccines
frequently elicit significantly different responses to the various B. pertussis antigens.
Despite lot to lot variation, benefits associated with whole cell vaccines clearly
outweigh the risks of side effects associated with pertussis vaccination. Some side
effects of vaccination include fever, redness or swelling at the site of vaccination,
persistent crying; neurological damage following vaccination has never been
conclusively proven. Nevertheless, increasing concern about adverse effects of
immunisation with whole cell preparations of B. pertussis has led to decreased
acceptability of whooping cough vaccination and a consequent increase in the
incidence of the disease (Robinson et al., 1985). It is imperative that an effective,
non-reactogenic vaccine of higher acceptability be developed. Thus, scientific

research is presently focused on the development of recombinant whooping cough
vaccines consisting of characterised constituents of the bacterium B. pertussis.

1 .3

Progress to Date in the Development of Recombinant Pertussis
Vaccines

Research is presently aimed at using genetic studies and recombinant DNA
technology to produce vaccines of higher efficacy than the whole cell vaccine. Such
new generation vaccines are likely to contain detoxified pertussis toxin (PT),
filamentous hemagglutinin (FHA), pertactin (P69) and possibly serotype specific
fimbriae. The genetic regulation of these virulence determinants provides vital
information for vaccine development.

1 .3 .1 The Genetic Regulation of Bordetella pertussis Virulence
Determinants

B. pertussis regulates the expression of its virulence determinants in a coordinated
manner in response to environmental stimuli. Regulation occurs via a sensory
transduction system encoded by the BvgAS (Bordetella Virulence Genes) locus
(Stibitz and Yang, 1991; Weiss and Hewlett, 1986). Although all of the known
virulence determinants of B. pertussis are regulated by the Bvg locus, PT and
adenylate cyclase toxin (ACT) also require auxiliary proteins for their transcription
(Miller et al., 1989). A Bvg accessory factor (Baf) has recently been partially
characterised. This work indicates that Baf, a novel transcripitional regulator,
interacts with BvgAS to transactivate ptx-lacZ fusions in E. coli (DeShazer et al.,
1995).

3
A schematic model of B. pertussis virulence gene regulation is presented in Figure 1.

x

fhaB
bvgAS
p rn l (pertactin)
fim i (serotype specific fimbriae)

ptx (pertussis toxin)
cya l (adenylate cyclase toxin)

Figure 1. Schematic model for virulence gene regulation on B. pertussis. Arrows indicate a positive
influence of gene expression. BvgA specifically binds to the promoter regions of fhaB and bvgAS
and activated transcription from these loci. Both Baf and BvgAS are needed in trans for transcription
of ptx (and possibly cya). The BvgAS system is necessary for activation of prn and fim in B.
pertussis , but it is unknown whether fim and prn require an accessory factor for expression or if
activation by Bvg is direct. The requirement of an additional factor (X) for the expression of Baf is
suggested. Taken from (DeShazer et al., 1995).

The bvgAS operon encodes two proteins: BvgA a transcriptional control factor, and
BvgS a transmembrane sensor protein. Current models suggest that BvgS activates
BvgA by a mechanism involving phosphorylation. Activated BvgA then binds to
specific sequences located upstream of regulated promoters to induce transcription of
virulence determinants. The stimuli that regulate the activity of BvgAS in the human
respiratory tract have yet to be determined. In vitro, however, the presence of sulfate
anions, nicotinic acid and low temperature (30°C) result in the cessation of
transcription of BvgAS activated genes and the induction of the negatively controlled
virulence repressed genes designated vrg (Knapp and Mekalanos, 1988; Lacey,
1960; M iller et al., 1989). The absence of these inducing factors results in the
induction of virulence activated genes (yag) and maximal expression of the virulence
determinants. Figure 2 summaries the role of the bvg locus in directing the
expression of vag and vrg loci.

4
bvgocus
l

Active

------------------------------------------ ►

Activation of
loci
Repression or vrg loci

4

A

Environm ental
signals

f

A ntigenic
m odulation

Y

Inactive bvg lo c u s _______________________________ No activation of vag loci
Repression lifted on vrg loci

Figure 2. Representation o f the pivotal role played by the bvg locus in regulating gene expression
in response to environmental stimuli, vag loci, v/r-activated genes; vrg loci, v/r-repressed genes.
Taken from (Coote, 1991).

The induction and repression of the bvg locus demonstrates that B. pertussis has the
ability to alternate between virulent and avirulent forms. This ability to alter
expression of the virulence determinants in response to environmental signals is
termed antigenic modulation. It has been suggested that the avirulent phase may
represent an intracellular, pathologically dormant state associated with late infection
and may be a strategy for immune evasion and thus persistence of the disease
(Coote, 1991).

1 .3 .2 V accine C om ponents

The virulence factors of B. pertussis

that are being considered as vaccine

components have been studied in detail. Following their cloning and sequencing, the
aim generally has been to produce these proteins using an appropriate expression
vector system. Additionally, in the case of toxins research has been conducted to
create mutations which detoxify the protein whilst preserving its immunogenicity.

Current research indicates that PT, FHA and P69 should be constituents of

recombinant vaccines. Evidence showing that vaccines provide increased protection
and longer lasting immunity with the incorporation of serotype specific agglutinins
also suggests the importance of these proteins as constituents of recombinant
vaccines (Miller et a l, 1991). However other studies suggest that serotype specific
fimbrial proteins offer no additional benefit as vaccine constituents (Edwards and
Decker, 1996).

1 .3 .2 .1

P e rtu ssis T oxin

The genes encoding the PT subunits are organised into an operon (Figure 3) (Nicosia
et al., 1986; Locht and Keith, 1986), which is not expressed when cloned into
Escherichia coli (Nicosia and Rappuoli, 1986). This protein is expressed by virulent
B. pertussis due to the ability of the Bvg locus to transactivate the PT promoter
(Arico e t a l , 1989).

Pr

i— i n n n i
SI

S2
ptx

S4 S5

ii ii ii
S3

A

B

i u u u u _l

ii
C

D

I

E

F

G

H

ptl

Figure 3. Schematic representation o f the PT operon and the pertussis toxin liberation (ptl) genes.
The five genes are clustered within a 3.2 kilobase DNA fragment in the following order: S I, S2,
S4, S5, S3. The ptl region o f the B. pertussis chromosome is 9.5 kilobases in length and is located
directly downstream from the PT structural genes. Pr indicates the location o f the ptx-ptl promoter.
The arrows indicate the direction of transcription, filled boxes represent signal peptides. Downstream
o f this operon, nine open reading frames have been identified coding for ptl genes , involved in PT
excretion. Adapted from (Farizo et al ., 1996).

The five PT subunits are thought to be exported individually into the periplasmic
space where holotoxin assembly occurs, before excretion of holotoxin into the
culture medium which is mediated by the PT liberation genes (ptl) genes (Weiss et
a l., 1993; Covacci and Rappuoli, 1993; Johnson and Burns, 1994). For the
purposes of this review excretion refers to the excretion of protein into the
extracellular environment, whilst secretion refers to secretion into the bacterial

periplasm unless otherwise stated. Secretion can be accomplished without the ptl
gene products; excretion of PT is only possible in the presence of ptl gene products.
A similar process has been proposed for the excretion of pullulanase from E. coli
(Pugsley et al., 1991) and excretion of enterotoxin from Vibrio cholerae (Hirst and
Holmgren, 1987). The ptl locus of B. pertussis encodes nine proteins (Farizo et al.,
1996; W eiss et al., 1993) that may form a gate or channel used in the transport
process (Johnson and Bums, 1994). The process of holotoxin assembly occurs
independently of ptl genes or other bvg-activated chaperone proteins (Walker et al.,
1991b).

Pertussis toxin, a 106 kDa hexameric protein, is a typical A/B bacterial toxin
(Tamura et al., 1982), containing functionally distinct domains responsible for
binding to cell surfaces and for catalytic activity. Other members in this toxin family
include cholera, Shiga, Pseudomonas exotoxin A and diphtheria toxin. PT, in
addition to being a presumptively vital protective immunogen, is a major component
in bacterial pathogenesis and has been advocated as the major cause of harmful
systemic effects (Pittman, 1979 and 1984). As shown in Figure 4, PT is composed
of five subunits, having two functionally different activities. The A-protomer or S 1
subunit is the enzymatic portion of the toxin which is activated by the reduction of a
single disulfide bond. Its functions include the ability to ribosylate target guaninenucleotide binding G proteins (Katada and Ui, 1982), which are membrane
associated molecules that transduce receptor-coupled agonist signals involved in the
reduction of adenylyl cyclase. PT functions by blocking adenylyl cyclase inhibition,
thereby resulting in the uncontrolled formation of cAMP, ultimately leading to
cytotoxic effects. In vitro, its presence results in the clustering of Chinese Hamster
Ovary (CHO) cells (Hewlett et al., 1983). The B-oligomer consists of subunits S2,
S3, S4 and S5 in a ratio of 1:1:2:1 (Tamura et al., 1982) and is responsible for
targeting toxic activity via cell surface receptor recognition. The S2 and S3 subunits
possess greater than 70% amino acid identity (Locht and Keith, 1986; Nicosia et al.,
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1986).

These subunits each contain distinctive eukaryotic cell receptor recognition
characteristics (Katada and Ui, 1982) and can display receptor attachment in vitro,
recognising lactosylceram ide and gangliosides from cilia and macrophages
(Saukkonen et al., 1992). The B-oligomer presumably acts as a delivery platform for
transmission of S 1 to sensitive host cells. Other in vitro binding capabilities of the Boligomer result in hemagglutination and lymphocyte mitogenicity. Dominant B and
T-cell epitopes of S2 (residues 78-98) are positioned just above the selectin-like
binding domain, which in eukaryotes are involved in lymphocyte trafficking. Two
other known antigenic determinants are parallel to each other; B and T cell epitopes
of S4 (residues 20-50) and a T-cell epitope at the interface of S3 and S4. Important
B-cell epitopes are contained in the SI subunit, including a dominant toxin
neutralising epitope (Burnette, 1994).

Sialic A dd
Glycoconjugate
Recognition
Site

Figure 4. The structure o f PT. A dominant mouse protective epitope is present on the SI subunit
which also contains an internal disulfide bridge, reduction of which is necessary for enzymatic
activity. The B-oligomer contains less dominant epitopes (but perhaps more important), a cilia
specific adherence site is present on the S2 subunit recognising glycolipids containing
lactosylceramide and glucosylceramide, whilst the S3 subunit possesses recognition sites for sialic
acid in the bronchoalveolar macrophages. Not drawn to scale. Adapted from (Burnette, 1990).

Immune responses towards the S 1 subunit and B-oligomer of PT have been shown
to be important in providing protection against toxin activity and B. pertussis
infection in animal models; research suggests that there is a correlation between
antibody and/or cell mediated immune responses against PT and protection against
human disease (Burnette, 1994). Several groups have developed strategies to
produce individual PT subunits or fusion proteins for use in experimental anti-PT
vaccines (Burnette et al., 1988a; Nicosia et al., 1987). Initial attempts include the
expression in E. coli of separate PT subunits as heterologous proteins fused to MS2
DNA polymerase. Whereas mice immunised with all five subunit fusion proteins
were not protected from intracerebral challenge with virulent B. pertussis, native
pertussis holotoxin was protective (Nicosia et al., 1987). The mouse intracerebral
challenge assay (Kendrick test; Kendrick et al., 1947) is the standard method for
measuring potency of commercial whooping cough vaccines. Burnette et al.
(1988a) attempted to directly express the five PT subunits separately in E. coli.
Initially this group expressed the five subunits with their native leader sequences
attached, however only the S 1 subunit leader sequence was found to be completely
processed. The S2 and S5 subunits were partially processed, whilst S3 remained
unprocessed and S4 was not expressed. When the native leader sequence was
replaced with a methionine intiation codon the production of mature protein was
achieved for all subunits. These proteins were expressed as insoluble inclusion
bodies in E. coli at levels ranging from trace amounts to 43.8% of the total cell
protein. Once again, mice immunised with all five recombinant subunit proteins
were not protected from intracerebral challenge with virulent B. pertussis, probably
because assembly of the holotoxin is required for the correct presentation of
protective epitopes (Bartolini et al., 1988; Burnette et al., 1992b).

An alternative to expression of B. pertussis antigens in E. coli, is to express such
antigens in Bordetella spp. under control of the native B. pertussis or a heterologous
promoter. A further aim of recombinant expression is to produce detoxified PT in
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avirulent strains of Bordetella spp. to prevent the copurification of other virulence
determinants and to increase the growth rates and yield of protein for vaccine
purposes. Mini-transposons have been utilised to stably integrate the PT operon into
the chromosome of bvg-negative B. bronchiseptica ATCC10580. In this instance
high level expression of PT from a B. bronchiseptica host promoter was achieved,
however PT was not secretedlnto the culture medium (Walker et al., 1991b). In
subsequent work, the same PT expression locus was transferred to virulent and
avirulent strains of B. bronchiseptica, however PT expression was again found to be
cell associated, suggesting the requirement of ptl gene products for secretion (Smith
and Walker, 1996). In a recent study, a mini-transposon containing the PT operon
was integrated into the chromosome of B. bronchiseptica and PT was found to be
stably expressed and present in the periplasm. Stable expression was achieved by
the use of a tightly regulated promoter under the control of an aromatic inducer
(Suarez et al., 1997). Another strategy involved the construction of B. pertussis
strains that overproduced genetically detoxified PT, this was achieved by
introducing additional copies of the PT operon into the B. pertussis chromosome at
the tox and fha loci. These strains where found to excrete up to 80 mg/1 of PT and
were stable under fermentation conditions (Zealey et al., 1992).

Attempts to reconstitute pertussis holotoxin from recombinant purified subunits in
vitro have so far resulted in low yields. Following renaturation experiments,
Burnette et al. (1992a) achieved a molar yield of 26% B-oligomer. Pertussis
holotoxoid has also been assembled in vitro from native B-oligomer and recombinant
SI purified and refolded from inclusion body preparations (Bartley et al., 1989). The
production of recombinant detoxified PT in E. coli would allow its biological
separation from those factors that may contribute to the reactogenicity of traditional
vaccines. It would also use the wealth of fermentation and purification technology
for recombinant E. coli in the high level expression and purification of genetically
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Attempts to reconstitute pertussis holotoxin from recombinant purified subunits in
vitro have so far resulted in low yields. Following renaturation experiments,
Burnette et al. (1992a) achieved a molar yield of 26% B-oligomer. Pertussis
holotoxoid has also been assembled in vitro from native B-oligomer and recombinant
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vaccines. It would also use the wealth of fermentation and purification technology
for recombinant E. coli in the high level expression and purification of genetically

detoxified pertussis holotoxin for vaccine purposes. Previous work on the
expression of PT in avirulent B. bronchiseptica demonstrated that recombinant
pertussis holotoxin and dimérisation of S3 and S4 subunits occurs in the periplasm
independent of frvg-activated gene products (Walker et a l , 1991b) These results
suggest that after the five subunits of PT are secreted to the periplasm, pertussis
holotoxin forms without the involvement of the ptl genes or other frvg-activated
chaperone proteins.

The potent activities of PT requires that it be detoxified prior to its inclusion into
acellular vaccines. Chemical methods such as gluteralderhyde, formaldehyde or
hydrogen peroxide used to detoxify PT are not considered satisfactory since they
produce a product with reduced immunogenicity, which may under certain
circumstances revert to toxicity (Table 1) (Storsaeter et al., 1988). However, initial
acellular vaccines contained chemically detoxified PT (Rappuoli, 1996). In a recent
field trial it was found that antibody levels in children were not correlated with the
quantity of PT antigen in vaccines, but more so with antigen deviation (Edwards et
al., 1995). In this respect genetically detoxified PT was superior to chemically
detoxified PT since its similar conformation to native PT resulted in superior
immunogenicity. Additionally, only genetic detoxification can guarantee the absence
of PT, which is toxic in minute quantities. Genetic detoxification is the current
method of choice for the production of a suitable vaccine component.

Several genetically detoxified analogues of pertussis holotoxin, expressed in either
B. pertussis, B. parapertussis, or B. bronchiseptica have been developed (Bartley et
al., 1989; Burnette et a l, 1988b; Kimura et a l, 1990b; Loosmore et al., 1993;
Loosmore et a l, 1990; Nencioni et a l, 1990; Pizza et a l, 1989; Zealey et a l, 1992).
The generation of a 12 base pair insertion in the SI subunit gene of B. pertussis
(Kimura et a l, 1990b) has resulted in an excreted PT mutant with reduced enzymatic

and biological activity that was found to be protective in a mouse lethal aerosol
challenge. Research by Loosmore et al. (1993), utilised site directed mutagenesis to
create PT analogs containing mutations in the B-oligomer; these mutants were found
to have toxin neutralisation activity and were protective in the mouse intracerebral
challenge assay. However, the most promising toxoid for vaccine purposes
(9K/129G) contains a double mutation in the SI subunit where Arg-9 is replaced
with Lys and Glu-129 is replaced with Gly via site directed mutagenesis (Nencioni et
al., 1990). This toxoid has been extensively characterised and found to possess
similar biological properties to native PT, apart from toxicity as measured by a CHO
clustering assay (Table 1). The toxoid 9K/129G is now a constitute of a licensed
acellular vaccine preparation and was field trialled in Italy (Gustafsson et al., 1996).
Other PT S 1 subunit mutants have also been made with reduced enzyme activity and
conserved protective epitopes (Burnette et al., 1988b; Loosmore et al., 1990; Pizza et
a l, 1989).
Table 1. Comparison of genetic versus chemical detoxification on the properties of PT.

Detoxification
Property

Purified toxin

Toxicity
Enzymatic activity
Receptor binding
Functionality of
B fragment
Shape
T-cell epitopes
B-cell epitopes

+
+
+
+

defined
+
+

Genetically

Chemically

_a
+
+

- /+ b
“

+

fuzzy
_c

defined
+
+

-/+

a Chemical detoxification reduced toxicity by several logs, however reversion to toxicity may occur.
b Chemical detoxification may reduce but not abolish the in vitro enzymatic activity.
c Although formalin-treated toxoids are able to induce T-cell immunity when used for vaccination,
they are less efficient in doing so then genetically detoxified molecules. This effect is more evident
in vitro , where chemically detoxified toxoids are unable to stimulate antigen-specific T-cells
(DiTommaso et al., 1994). Adapted from (Rappuoli et al., 1995)
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Apart from expression of PT or PT subunit genes in E. coli or Bordetella spp., only
a limited number of studies have investigated production of this protein using
alternative expression systems. High level expression and secretion of the S 1 subunit
of PT has been achieved in the Gram-positive, endotoxin-free bacterium Bacillus
subtilis. In this system, the gene encoding the S 1 protein was inserted into a alpha
amylase secretion vector under control of the alpha-amylase gene promoter; yields of
up to 100 mg/1 of SI were achieved (Runeberg-Nyman et al., 1987). In another
study using the Gram-positive bacterium, Streptomyces lividans, expression and
excretion of PT S 1 was attained. In this study the DNA encoding the S 1 gene was
fused to the regulatory elements of the xylanase A gene (xlnA) with the coding
region of the leader peptide (with and without the truncated structural gene of XlnA).
Yields of the protein in S. lividans were estimated at 1 mg/1; this low yield was
thought to be a result of susceptibility of the protein to secreted proteases (Paradis et
al., 1996). In similar work, the S2 subunit of PT has been expressed and excreted in
Bacillus brevis, the yield of recombinant protein was found to be 70mg/l (Kozuka et
a l , 1996).

It has been proposed that other components of B. pertussis

may confer

immunoprotection, possibly by eliciting antibodies that inhibit bacterial attachment to
the respiratory epithelium and prevent subsequent colonisation. In this respect
research has focused on FHA, P69, serotype specific fimbriae and ACT.

1 .3 .2 .2

Filamentous Hemagglutinin

Filamentous hemagglutinin is the major adhesion of B. pertussis and is a secreted
polypeptide product, appearing as fine filaments when released from the bacterium
(Locht et a l , 1993). This protein plays a major role in bacterial attachment and
colonisation of the epithelial respiratory tract (Reiman et a l, 1989). Studies using

Tn5 induced mutants deficient in the production of both FHA and fimbriae showed
no decrease in virulence in infant mice as assessed by determining the LD 50
following intranasal challenge (Weiss and Goodwin, 1989). However, B. pertussis
strains containing mutations in the structural gene fhaB were unable to colonize the
upper respiratory tract, but instead could be recovered from the alveoli and were
shown to persist in the lungs (Kimura et al., 1990a). These results suggest that FHA
may not be essential for colonisation of the lungs, but that it is important for initial
adherence to the trachea. Efficient lung colonisation is most likely a multifactorial
process. In vitro, FHA mediates numerous binding activities including attachment to
cilia and then binding back to the bacterial surface, creating an adherence bridge
(Tuomanen and Weiss, 1985; Tuomanen and Hendley, 1983).

The DNA sequence encoding FHA has been cloned and found to be composed of an
operon containing three genes; fhaA, the structural gene fhaB, and fhaC. The gene
encoding the structural protein FhaB has been sequenced; this information suggests it
is derived from a longer polypeptide by COOH-terminal cleavage (Reiman et al.,
1989). The excretion of FHA into the extracellular milieu is dependant on the outer
membrane accessory protein FhaC. The FHA structural and accessory genes are
located adjacent to the bvgAS genes and are directly activated by the bvgA gene
product (Figure 5). Thus,fh a genes together with bvg genes are the very first to be
activated after entry of B. pertussis into the host. Once inside the host FHA can bind
to both ciliated and non-ciliated epithelial cells, the first cells encountered in
infection. The binding of FHA to ciliated cells indicates the presence of a lectin-like
binding domain, whilst a heparin-binding domain has been shown to interact with
non-ciliated cells. FHA also possesses a RGD binding site (Reiman et al., 1990)
involved in its binding to the leukocyte integrin CR3, possibly the only known
example of a prokaryote using a eukaryote recognition motif to bind an integrin. This
interaction triggers invasion without generation of an oxidative burst, thus allowing
intracellular survival.
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membrane accessory protein FhaC. The FHA structural and accessory genes are
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interaction triggers invasion without generation of an oxidative burst, thus allowing
intracellular survival.
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Figure 5. Schematic representation o f the structure o f the bvg/fha/fim locus. The respective open
reading frames are indicated by open boxes, filled boxes indicate signal peptide regions. The direction
o f transcription is indicated by arrows, the dashed line represents the possible read-through that can
occur from the fhaB gene. Not drawn to scale. Adapted from (Locht et a l, 1993).

The FHA gene has previously been cloned and expressed in E. coli (Brown and
Parker, 1987; Delisse-Gathoye et al., 1990). Guzman et al. (1991a) have also
successfully expressed FHA in E. coli K-12 and Salmonella typhimurium aroA at
levels higher than those found in wild-type B. pertussis. This was accomplished by
replacement of the native upstream signals of the gene and the modification of the
translation initiation region to optimize translational efficiency. Additionally,
inclusion of a section of the COOH-terminal FHA open reading frame was shown to
be important in achieving expression of the recombinant protein. High level
expression of FHA in E. coli may lead to the elimination of the problems
encountered in its production from B. pertussis. These problems include the co
purification of toxins present in B. pertussis and the safety aspects involved in
growing a human pathogenic bacterium. Expression in S. typhimurium aroA may
also permit the development of live vaccine carrier strains expressing pertussis
antigens and the opportunity to develop oral whooping cough vaccines that offer
both mucosal and systemic immunity (Charles and Dougan, 1990; Hoiseth and
Stocker, 1981). Research has indicated that active immunisation with FHA or
passive immunisation with antibodies to this protein significantly reduced B .
pertussis colonisation in mice (Kimura et al., 1990a). Other studies by Roberts et al.
(1993) and Calhill et al (1993) have shown that intranasal administration of FHA into
mice induces protection following aerosol challenge, in addition to generating a local
secretory antibody response in the lungs. The protection afforded by this

protein makes it a likely component for recombinant pertussis vaccines, indeed, the
majority of acellular pertussis vaccines contain FHA. The addition of FHA to vaccine
preparations containing only PT appears to marginally increase the protective efficacy
o f such vaccines in children (Adhoc Group, 1988).

1.3.2.3

P69 (Pertactin)

In addition to PT and FHA, new generation vaccines may also include P69. This
protein is a virulence factor of B. pertussis localised in the outer membrane of the
bacterium and is believed to play a role in attaching the bacterium to epithelial cells
lining the respiratory tract mucosa (Leininger et al., 1992; Roberts et al., 1992). The
gene encoding P69 (prn) has been sequenced and found to be derived from a 93kDa
precursor by cleavage of the NH2-terminal signal peptide and removal of a COOHterm inal fragm ent (Charles et al., 1988). This protein has recently been over
expressed in B. pertussis using chromosomally integrated genes controlled by hybrid
PT or FHA promoters. The resulting protein was expressed at significantly higher
levels then the wild-type protein and was found to be excreted (Loosmore et al.,
1995). High level production of P69 has also been achieved from the yeast Pichia
pastoris using a yeast expression vector; the protein yield in this study was 3mg/l
(Romanos eta l., 1991).

Purified P69 has been shown to contribute to the protection of mice against an
intracerebral challenge with B. pertussis (Novotny et al., 1985; Shahin et al., 1990).
In an intranasal challenge assay in mice it was demonstrated that P69 used alone as
an immunogen afforded significant protection against lung colonisation and against a
lethal challenge with a hypervirulent strain of B. pertussis (Capiau et al., 1990). In a
study that assessed both humoral and cellular immunity against B. pertussis
antigens, it was found that intranasal immunisation of mice with P69 greatly

increased their ability to clear B. pertussis infection in the lungs following aerosol
challenge (Roberts et a l., 1993). In this study, protection was found to correlate
better with T-cell proliferation of isolated spleen cells than with antibody responses,
indicating the role of cell mediated immunity in the elimination of bacteria from the
respiratory tract. A recent field trial in infants has demonstrated that the inclusion of
P69 increased the protection afforded by a bivalent (PT, FHA) vaccine (Greco et al.,
1996).

1.3.2.4

Serotype Specific Fimbriae

Serotype specific fimbriae are filamentous surface antigens that stimulate antibody
production causing bacterial cell agglutination and thus the serotype specificity of
bacteria producing immunologically different fimbriae. At least three types of
fimbriae are produced by B. pertussis, serotype 2 and serotype 3 fimbriae being the
most prevalent. Using these specialised surface structures the bacteria can adhere to
the upper respiratory tract epithelium (Urisu et al., 1986) and thus escape clearance.
The fim accessory genes are co-transcribed with the fhaC accessory gene of FHA in
a polycistronic operon (Figure 5), suggesting that fimbriae may act in conjugation
with FHA during the initial steps of B. pertussis infection.

The serotype 2 fimbrial subunit protein has previously been expressed in E. coli
CAG629 (a Ion protease and heat shock protease deficient strain), and its filamentous
products have been shown to be auto-assembled in vitro (Walker et al., 1990). In
this study, protein expression was achieved by replacement of the upstream signals
of the fimbrial subunit gene with the lambda

Pr

and

Pl

promoters and the E. coli

atpE translational initiation region. The detection of cell surface associated fimbrial
structures, however, was not apparent. The use of an expression/secretion vector
pC G V l in combination with E. coli strains containing a leaky outer membrane has

subsequently been shown to result in the excretion of fimbrial subunits into the
extracellular medium (Guzman et al., 1995). Recombinant serotype 2 fimbriae have
also been produced in virulent B. parapertussis and B. bronchiseptica under control
of the lac promoter. Expression of serotype fimbriae in Bvg-negative (avirulent) B.
bronchiseptica was not apparent, suggesting that fimbrial accessory genes are
important for expression of these antigens (Walker et al., 1990).

In a field trial conducted by Miller et al. (1991) an acellular vaccine containing
fimbriae in addition to PT and FHA was trialled in infants. They found that the
persistence of antibodies after vaccination was higher in the acellular vaccine which
produced significantly less symptoms compared to the conventional whole cell
vaccine. It was suggested that the inclusion of fimbrial antigens in an acellular
vaccine may enhance protection against infection as well as disease, which was not
found for acellular vaccines containing only PT and FHA. In contrast to this field
trial, recent field trials have shown no increase in vaccine efficacy when fimbriae
were included in the vaccine preparation, suggesting that they are not required for a
protective immune response (Edwards and Decker, 1996). Clearly, additional
research into the protective efficacy of these proteins need to be undertaken to
determine their vaccine potential.

1 .3 .2 .5

Adenylate Cyclase Toxin

Adenylate cyclase toxin (ACT) is composed of a single polypeptide possessing both
catalytic and toxin activities. This toxin is mainly cell associated, but is capable of
being released into the extracellular environment. ACT acts by penetrating
mammalian cells and interacting with calmodulin, a eukaryotic calcium-binding
protein, generating uncontrollable levels of cyclic AMP (Confer and Eaton, 1982;
Hanski and Farfel, 1985). Thus ACT has the same biological effect as PT but
achieves it by a different mechanism.
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The gene encoding ACT has been sequenced and found to contain a single
bifunctional protein (Cya A protein or cyclolysin) which endows both adenylate
cyclase and hemolytic activities. The toxin has been expressed in E. coll, and has
also been shown to possess protective activities in a murine respiratory model
(Betsou et al., 1993; Sebo et al., 1991). Additionally, it has been shown that both
active and passive immunisation with ACT significantly shortens the period of
bacterial colonisation in the murine respiratory tract (Guiso et al., 1989; Guiso et al.,
1991). Furtherm ore, anti-ACT antibodies have been detected in the sera of B .
pertussis infected humans (Arciniega et al., 1991; Guiso et al., 1993).

1 .3 .3 Field Trials of Whole Cell and Acellular Vaccines

Although acellular vaccines have been licensed for more than 15 years in Japan,
research concerning the protective efficacy of individual components of the vaccine
have only been conducted in detail recently. When the Japanese acellular vaccine was
first introduced the only efficacy requirement for its potency was the mouse
intracerebral challenge assay. Acellular vaccines have been highly successful in
Japan, producing good antibody responses and decreased reactogenicity compared to
whole cell vaccines (Aoyama, 1996). With the advent of improved techniques for
antigenic characterisation, researchers have worked to produce acellular vaccines
whose components are more genetically defined in order to reduce lot to lot variation
and offer increased protection compared to these original acellular vaccines and
whole cell vaccines.

As humans are the only reservoir for whooping cough, human field trials represent
the only possible way and final step involved in realistically testing the efficacy of
new pertussis vaccines. Field trials are generally undertaken in three phases; phase I
and phase II trials involve immunogenicity, generation of limited safety data, study
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of doses and vaccination schemes. The phase III trials evaluate efficacy in field trials,
household contact studies or challenge study settings where vaccinated infants are
monitored following exposure to disease. In the mid 1980's the first phase III trial of
major significance with respect to acellular vaccines was undertaken in Sweden at a
time when the banning of the whole cell vaccine had resulted in a pertussis epidemic
in that country (Adhoc Group, 1988). The vaccines tested were comprised of
purified components from wild-type B. pertussis. The first vaccine trialled consisted
of chemically detoxified PT and FHA, whilst the other was comprised of chemically
detoxified PT alone. The results of this field trial found that whilst producing good
antibody responses, neither vaccine gave adequate levels of protection in infants.
Thus the antibody response did not correlate with the levels of protection observed.
Both vaccines were protective against severe disease, but the mono-component
vaccine showed no protection against infection, whilst the two component vaccine
showed incom plete protection against infection (Storsaeter et al., 1990). These
acellular vaccines probably gave rise to less adverse side reactions than whole cell
pertussis vaccines, however no whole cell control was used in this trial (Table 2).

Genetically or chemically detoxified PT is the central component of new generation
whooping cough vaccines currently being developed or licensed for general use. For
instance, a phase III human field trial testing a vaccine containing chemically
detoxified PT (in combination with diphtheria and tetanus toxoids) found that the
efficacy of this single antigen was 71% (Trollfors et al., 1995). Various phase III
field trials have also been undertaken using vaccines containing purified components
which include combinations of genetically or chemically detoxified PT, FHA,
fimbriae and P69 (Table 2) (Greco et al., 1996; Gustafsson et al., 1996; Schmitt et
al., 1996). In these field trials the efficacy of all the acellular vaccines was superior
to that o f the whole cell vaccines. Additionally, rates of adverse reactions were
substantially lower in the acellular vaccinees compared to those vaccinated with the
whole cell preparation, however, side effects were not eliminated.
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Table 2. Summary o f important field trials o f pertussis vaccines.
Number of
Vaccinées Efficacy

Vaccine

Country

Pa (PT*, FHA, P69)
Pw

Germany

22505* 88.7*
97.6*

(Schmitt et a l , 1996)

Pa (PT*, FHA)

Sweden

9829

58.9
85.2
48.3

(Gustafsson et a l , 1996)

Italy

15601

84
84
36

(Greco, étal., 1996)

Sweden

3801

54

(Adhoc Group, 1988)**

Pa (PT*, FHA, P69, FIM 2,3)
Pw
Pa (PT*, FHA, P69)
Pa (PT§, FHA, P69)
Pw
Pa (PT*)
Pa (PT*, FHA)

Reference

69

Pa = acellular pertussis vaccine.
Pw = whole cell pertussis vaccine.
^Vaccinated with Pa.
^Determined attack rates in house hold contacts o f index pertussis cases (diagnosed as spasmodic
cough for at least 21 days with cultural or serological confirmation).
^Chemically detoxified.
^Genetically detoxified.
**No whole cell control was used.
A ll vaccines were given as component o f DTP.
Adapted from (Boughton, 1996).

In the Italian trial, which compared the efficacy of three component vaccines
containing genetically or chemically detoxified PT, it was found that only the
genetically detoxified PT vaccine was able to confer protective immunity starting
after the first vaccine dose, allowing protection of the most vulnerable (Rappuoli et
a l , 1995),

In a study undertaken to determine the impact of the introduction of acellular
pertussis vaccines as fourth and fifth booster doses in the USA and Canada, 27
million whole cell pertussis DT and 5 million acellular pertussis DT doses were
investigated for adverse reactions in children aged 15 months to seven years of age.
The results of this study are summarised in Table 3.
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*Determined attack rates in house hold contacts of index pertussis cases (diagnosed as spasmodic
cough for at least 21 days with cultural or serological confirmation).
^Chemically detoxified.
^Genetically detoxified.
**No whole cell control was used.
All vaccines were given as component of DTP.
Adapted from (Boughton, 1996).

In the Italian trial, which compared the efficacy of three component vaccines
containing genetically or chemically detoxified PT, it was found that only the
genetically detoxified PT vaccine was able to confer protective immunity starting
after the first vaccine dose, allowing protection of the most vulnerable (Rappuoli et
al., 1995). Differences observed in whole cell vaccines probably due to strain
variations, production processes or inclusion of adjuvants make comparisons
between these vaccines difficult.

In a study undertaken to determine the impact of the introduction of acellular
pertussis vaccines as fourth and fifth booster doses in the USA and Canada, 27
million whole cell pertussis DT and 5 million acellular pertussis DT doses were
investigated for adverse reactions in children aged 15 months to seven years of age.
The results of this study are summarised in Table 3.
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Table 3. Rates of adverse events within 72 hours after whole cell or acellular pertussis
vaccination.

Adverse Event

All Reports
Fever
Seizures
Hospitalized

Whole Cell Pertussis
Rate

Acellular Pertussis
Rate

9.8
7.5
1.7
0.9

2.9
1.9
0.5
0.2

All vaccines were given as a component of DTP vaccines. Rates are per 100,000 doses
Adapted from (Rosenthal et al ., 1996).

As indicated by the rates of adverse reactions shown in Table 3, the current acellular
vaccines used in the USA and Canada are approximately three times less reactogenic
compared to whole cell vaccines. However the future goal of researchers is to
develop vaccines that completely eliminate adverse reactions.

Cell Mediated Immune Responses in Infants

W hooping cough has previously been considered to be a non-invasive mucosal
infection, resulting in a toxin-mediated disease (Pittman, 1979). Thus, the majority
of research concerning the immune response to pertussis infections has focused on
humoral immunity. However, recent findings suggest that B. pertussis can invade
eukaryote cells (Ewanowich et al., 1989) and the detection of antigen-specific CMI
responses (DeMagistris et al., 1988; Mills et al., 1993; Petersen et al., 1992) has
prompted a re-evalutation of potential protective mechanisms. In a recent study in
was found that an acellular pertussis vaccine consisting of chemically detoxified PT
together with FHA and P69, was able to induce an antigen-specific CMI response in
infants following vaccination (Zepp et a l, 1996). The CMI response was found to
increase over the entire vaccination schedule; this response was strong and stable
over the post-primary to pre-booster period, in contrast to declining antibody titres.
Cytokine profiles showed a preferential induction of 11-2 and gamma interferon

producing Th-1 cells and only a low 11-10 response. The induction of a CMI
response in the absence or with only a low antibody response may explain the
results of a number of recent field trials that have demonstrated the apparent lack of
correlation between serological antibody titres and protection (Adhoc Group, 1988;
Greco et al., 1996; Gustafsson et al., 1996; Schmitt et al., 1996). CMI responses
clearly require further investigation in order to improve the understanding of the
persistence o f protection following immunisation or natural infection with B.
pertussis.

1 .4

Vaccine Delivery Systems

The isolation and expression of potential recombinant vaccine components against
pertussis necessitates investigation o f vaccine delivery systems. Attenuated
Salmonella spp. have been utilised to express a variety of heterologous antigens,
then used as experimental vaccines. Antigens of B. pertussis including FHA
(Guzman et al., 1991a; Guzman et al., 1991b; Molina and Parker, 1990; Parker et
al., 1990), the SI subunit of pertussis toxin (Barry et al., 1996; Walker et al., 1992)
and P69 (Strugnell et al., 1992) have all been expressed and delivered to mice using
this system. Although attenuated Salmonella spp. probably represents the most
thoroughly characterised bacterial delivery system, other systems are presently under
investigation as potential carriers of foreign antigens to the immune system.

1 .4 .1 Bacille-Calmette-Guerin (BCG)

The w idespread use of the attenuated BCG vaccine against M yco b a cteriu m
tuberculosis has demonstrated its potential as a promising carrier of foreign antigens.
This vaccine has shown remarkably few side effects when delivered to the very
young (Lotte et al., 1984). Additionally, it has been shown to be an excellent
adjuvant; killed BCG in combination with Freund's adjuvant has been shown to

stimulate cellular immunity against M. leprae. When given this vaccine, many
leprosy suffers have in fact recovered (Dougan et al., 1989). BCG has also been
used to express antigens from Borrelia burgdorferi, the causative agent of Lyme
disease. Intranasal administration of this attenuated recombinant vaccine into mice
has been shown to result in long lasting protection against subsequent challenge with
the organism (Service, 1994).

1 . 4.2 Vibrio cholerae

Vibrio cholerae, the bacterium responsible for cholera, has also been used as a carrier
of foreign antigens to the immune system. This bacterium triggers both serum and
mucosal antibodies. As with Salm onella, this bacterium naturally colonises the
gastrointestinal tract, thus is readily processed by memory cells located on Peyer's
patches along the small intestine. A mutation in a gene locus encoding a major ironrepressed outer membrane protein (irgA) has been found to reduce the virulence of
this bacterium. Insertion of foreign genes downstream of the irgA promoter could
therefore generate antigen expression which may result in an immune response
(Butterton et al., 1993). A potential problem with the expression of foreign antigens
in V. cholerae is the induction of 'vector immunity' by the generation of antibodies
against the bacterium in the host. This is a problem because there are only two strains
or serotypes of V. cholerae. Therefore this bacterium will only have limited use as a
delivery system, as a vaccine for one disease could effectively render this carrier
useless as a carrier of other antigens. This is less of a problem with Salm onella
strains which contain more than two thousand serotypes, giving plenty of scope for
the selection of different delivery vehicles.
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1 .4 .3 Transgenic Plants

Recently, research has been undertaken towards developing oral vaccines based on
plant expression systems with the aim of administering dietary vaccines (Moffat,
1995). Transgenic potato tubers containing genes encoding E. coli heat-labile
enterotoxin (LT-B) have been shown to generate serum and gut mucosal anti LT-B
immune responses when administered by gavage or fed to mice. Additionally, these
immunoglobulins were capable of neutralising the entertoxin in cell protection assays
(Haq et al., 1995). Other groups have expressed the hepatitis B surface antigen in
plants (M ason et al., 1992) and generated and assem bled functional hybrid
antibodies (Ma et al., 1995). These studies indicate the feasibility o f expressing
foreign antigens in plants for use as oral vaccines of the future.

1 .5

Attenuated Salmonella as a Vaccine Delivery System

Salm onella spp. can be attenuated by the introduction of nonreverting defined
mutations into the bacterial genome to produce live vaccine strains. Several genes
have been identified that when mutated will attenuate this bacterium. Salmonella
strains harbouring mutations in the aromatic amino acid synthesis pathway make
excellent vaccines. Unlike parenteral vaccines which are delivered by intramuscular
injection and stimulate a systemic response, live oral vaccines envoke strong
humoral, local and cellular immune responses in the host. Because of the array of
immune responses induced by live oral vaccine strains, they have the potential to be
used for the delivery of heterologous antigens to the mammalian immune system.
Several antigens from foreign bacteria, parasites and viruses have been successfully
expressed in Salmonella vaccine strains (reviewed in Cardenas and Clements, 1992).
Such hybrid strains have the potential to be used as multivalent vaccines against a
number of infectious diseases.

25
1 .5 .1 Immune Response to Salmonella Species

As facultative intracellular pathogens, Salmonella spp. can invade a variety of
m ammalian epithelial cells. Humoral immunity to this bacterium is mediated by
antibodies which act to opsonise bacteria, resulting in enhanced phagocytosis by
macrophages and neutrophils. Cellular immunity involves the generation of cytotoxic
T-lym phocytes directed against the bacterium. The degree to which these two
immune responses control infection has remained controversial, since the immune
response is dependent on external variables such as route of immunisation, age of
vaccinee and vaccination schedule (O’Hagan, 1994). However, it is now thought
that antibodies alone cannot protect against Salmonella infections for long time
periods after oral vaccination. Cellular immunity may play a significant role in
generating a protective immune response (reviewed in Dougan et al., 1989).

1 .5 .2 The Advantages of Live Oral Vaccines

The majority of bacterial vaccines currently available are composed of killed micro
organisms. These vaccines can be administered parenterally, and as such generate
serum immune responses. Parenteral vaccines do not elicit a mucosal secretory
immunoglobulin A (IgA) response and in general are ineffective against organisms
that colonise mucosal surfaces and do not invade. Although such vaccines can be
highly efficacious they may induce undesirable side effects or show unsatisfactory
protection levels; for this reason in particular, much research has been directed
towards the use of live, attenuated vaccines.

Live attenuated Salmonella vaccines are believed to be superior to killed vaccines
because they provide sustained persistent antigenic stimulation in vivo. Live
attenuated pathogens can establish a limited infection in the host, leading to an
immune response which closely mimics that detected following infection with a

virulent pathogen. Infection by most bacterial pathogens occurs either at or via
mucosal surfaces. In vaccinating against disease, generation of an immune response
at these surfaces is therefore of upm ost importance. Orally administered live
attenuated vaccines strains such as Salmonella aroA are natural colonisers of the
gastrointestinal tract and therefore readily bind M-cells of the immune system and are
effective in inducing Th-2 cells that mediate specific IgA responses (Hoiseth and
Stocker, 1981). This probably occurs because antigen is delivered to the B and Tlymphocytes of the gut associated lymphoid tissue. The primed B cells then migrate
to the m esenteric lymph nodes and undergo differentiation. After entering the
thoracic duct the B-lymphocytes enter general circulation and reach all secretory
tissues of the body including the respiratory tract. The production of IgA by mature
plasma cells allows this immunoglobulin to be transported onto the mucosal surface
where it is available for interaction with invading pathogens (Cebra et aL, 1986). An
illustration of the traffic o f lymphocytes and the generation of mucosal immunity
through oral im m unisation is shown in Figure 6. This form of immunity is
particularly im portant in protecting against enteric pathogens which include
Salm onella spp. Such immunity cannot be satisfactorily generated by parenteral
vaccines.

_
.
.
Thoracic Duct
Salivary Glands
Sm all Intestine _______ M esentenc
_________________________ Respiratory Tract
(Peyer’s Patches)
Lym ph N odes
Breasts

Genitourinary Tract

Figure 6. Generalised pathway for the stimulation of specific mucosal immune responses. Adapted
from (Cardenas and Clements, 1992).
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1 .6

Salmonella Vaccines

The multifactorial characteristics of the Salmonella virulence factors and the lack of
acceptable adjuvants has encouraged a great deal of research towards developing
effective live attenuated Salmonella vaccines for oral administration. Such a vaccine
m ust be immunogenic, non-reactogenic, persist in host tissue for a limited time
period and should not carry genes for antibiotic resistance.

1 .6 .1 Typhoid Vaccine: Ty21a (gal E)

Initial studies on Salmonella spp. virulence relied on techniques that produced less
well defined mutations than those available today. In 1975 a live typhoid vaccine,
Ty21a was produced by chemical mutagenesis with nitrosoguanidine, so as to
contain a mutation in the galE gene (Germanier and Furer, 1975). This strain was
unable to incorporate galactose in sufficient quantities in the cell wall to allow the
synthesis o f smooth type lipopolysaccharides. Cells o f strain Ty21a given
intraperitoneally were found to protect mice against lethal challenge with S. typhi
(Germ anier and Furer, 1975). In human volunteers the vaccine showed a 87%
efficacy rate, undoubtedly providing protection against typhoid.

These encouraging results led to large scale field trials conducted in Egypt, and then
in Chile in the mid 1980's. In the Egyptian field trial child vaccinees received three
doses of a liquid vaccine and results showed an efficacy of 96%. The South
American trial was established in an area with a greater endemic rate of typhoid, and
a different vaccine formulation was used. Results showed'that the Ty21a vaccine
delivered in an enteric-coated-capsule gave an efficacy of 67% over a three year
period when administered to healthy young adult Chileans (Wahdan et ah, 1982;
W ahdan et al., 1980). The Ty21a typhoid vaccine is now licensed in a number of
countries including the United States and Australia.

Although Ty21a has proved successful as an effective typhoid vaccine, it does
exhibit a number of disadvantages. This vaccine requires multiple doses to achieve
acceptable immunogenicity (Tacket et al., 1992a) and is age dependent (Murphy et
a l., 1991). Additionally, the level of efficacy achieved is highly effected by the
vaccine formulation used and the immunisation schedule (Levine et al., 1989). Also,
the chemical mutagenesis method used to produce the vaccine inadvertently resulted
in m ultiple genetic lesions beyond those targetted (Levine et a l., 1987). The
problem s surrounding Ty21a have spurred the development o f new oral typhoid
vaccines. A number of individual genes in which mutations give rise to attenuated
Salmonella strains have now been identified.

1 .6 .2 Acya Acrp R e g u la to ry M u ta n ts

Apart from aro vaccine strains, the most thoroughly characterised Salm onella
mutants are the cya crp strains. These mutants lack adenylate cyclase and the cAMP
receptor protein respectively. Consequently such mutants exhibit slower growth than
wild type strains because these products are required for expression of numerous
genes and operons for carbohydrate transport and catabolism, glycogen synthesis
and amino acid and peptide transport and catabolism (Curtiss et al., 1993). Human
field trials in healthy adult volunteers showed that these S. typhi mutants were highly
immunogenic when given as a single oral dose. However, fever and bacteremia
occurred in 2 out of 12 volunteers (Tacket et al., 1992a).

1 .6 .3 p h o P a n d o m p R R eg u lato ry M u ta n ts

S. typhimurium phoP mutants are unable to survive within macrophages in vitro and
are avirulent in mice. The avirulence of this strain results from insertion of a
transposon into phoP , a regulatory gene responsive to phosphate levels and to
intracellular conditions within macrophages, such as low pH. Although these strains
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exhibit a poor ability to colonise the intestinal tract, they are highly immunogenic
(Galan and Curtiss, 1989). Transposon mutagenesis has also lead to the isolation of
strains deficient in one or more outer membrane proteins. The ompR gene is thought
to encode a positive regulator for the expression of other outer membrane proteins,
including a tripeptide permease and other as yet uncharacterised proteins involved in
nutrient transport and the exclusion of harmful substances from the bacterial cell.
These ompR m utants were avirulent in mice follow ing oral or intravenous
immunisation and were found to persist for several weeks in murine tissues (Dorman
et aL, 1989).

1 .6 .4 htrA Regulatory Mutants

The htrA gene is important for the survival of Salmonella in vivo. The product of this
gene is a stress induced serine protease, DegP. This gene product is necessary for
growth at elevated temperatures where it functions to remove incorrectly folded
proteins in the periplasm. Unlike aro mutants, these strains do not exhibit replication
in vivo and persist at lower levels in tissues than aro mutants. However either
combined with aro A or on their own these mutants make good single dose vaccines
(Chatfield et al., 1992).

1 .6 .5 Salmonella aro Auxotrophic Mutants

The aroA gene encodes an enzyme involved in the bacterial perchorismate pathway
which leads to chorismate synthesis, that in turn, leads to the generation of aromatic
amino acids including para-aminobenzoic acid and 2,4-dihydroxybenzoate, as
indicated in Figure 7. Bacteria which lack this gene product either do not replicate or
only do so to a limited extent as these two amino acids are essential but not available
in mammalian tissues. Salmonella aroA are still invasive, but the absence of these
essential amino acids accounts for the avirulence of the aroA strain (Hoiseth and
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Figure 7. The common aromatic biosynthetic pathway, to chorismic acid, and the products derived
from it which cannot be synthesized by aroA mutants. Adapted from (Cardenas and Clements,
1992).

S. typhimurium aroA strains were first developed in 1981 by the insertion of the
tetracycline resistant transposon TnlO into the aroA gene (Hoiseth and Stocker,
1981). These derivatives were shown to be avirulent and non-reverting.
Immunoprotection of mice against a virulent strain of S. typhi was also conferred by
this vaccine strain. In order to provide further evidence for their effectiveness as oral
vaccines, a num ber a studies have been undertaken using different strains of
Salm onella with mutations in the aroA gene. In a study conducted using mice
innately hyper-susceptible to S. typhimurium, it was found that S. typhimurium
aroA SL3235 induced high levels of long lasting immunity against challenge with
virulent S. typhimurium (Killar and Eisenstein, 1985). Another study has utilised
transposons in order to generate stable auxotrophic m utations in aroA o f S.
typhimurium strains which were virulent in mice. This aroA mutant was tested for its
ability to induce protective immunity in BALB/c mice and was found to be an
effective oral and intravenous vaccine, persisting for several weeks in the liver and
spleen (O’Callaghan etal., 1988).

S. typhimurium aroA strains administered as live oral vaccines have, in general, been
found to be safe in immunogenically competent and immunologically compromised
chicken, sheep and calves. These vaccines showed protection against lethal challenge
with virulent S. typhimurium generating both antibody and CMI (M ukkur
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et al., 1987; Smith et al., 1984; Stocker et al., 1983). S. typhimurium strains
harbouring defined mutations in several aro genes including aroA, aroC and aroD
either alone or in combination have been found to be attenuated to a similar level and
have the same immunogenic properties. Such vaccines with more than one genetic
lesion would be attractive for human use since the possibility o f reversion of a
double mutant would be remote (Chatfield et a l, 1993). Human field trials in healthy
adult volunteers, using a S. typhi double aro mutant (aroC, aroD) CVD908, have
shown that this strain was significantly more immunogenic after a single dose than
the current Ty21a after multiple doses, however bacteremias were observed in half of
the adult volunteers (Tacket et al., 1992a and 1992b). In another aroC, aroD strain,
CVD906, it was found that although this strain was highly immunogenic, fever was
observed in a significant proportion of volunteers (Hone et al., 1992). Recently
research has focused on new attenuating mutations in CVD906 and CVD608 vaccine
strains. These strains have been further engineered by deletion in htrA, the resulting
strains were assessed for immunogenicity in human adult volunteers. These strains
were found to be well tolerated and antibody responses against S. typhi
lipopolysaccaride and H antigens were observed in at least 75% of volunteers
(Tacket et al., 1997). If these S. typhi strains are found to be safe and confer
protection, they may be considered as replacements for S. typhi Ty21a, as carriers of
heterogenous antigens and for protection against typhoid.

1 .6 .6 A tte n u a te d Salm onella spp. as a C a rrie r of Foreign A ntigens

W ith the use of live oral Salmonella vaccines, a new strategy has emerged to deliver
foreign antigens to the immune system via the oral route. This is achieved by
introducing and expressing DNA from other pathogens into the live Salm onella
vaccine. Oral administration of these multivalent vaccines enable immunisation
against salmonellosis, as well as the potential induction of both mucosal and
systemic immune responses against the foreign antigen.
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One o f the first antigens to be delivered by Salmonella aro mutants was the B
subunit of the heat labile enterotoxin (LT-B) of E. coli (Clements et al., 1986;
Maskell et al., 1987). Using this antigen, it was possible to detect both systemic and
secretory antibody responses to the secreted LT-B protein. This initial work
encountered problems with plasmid instability when the tac promoter was used.
Although the use of the lac repressor stabilised the plasmid, expression was reduced
to an extent such that no immune response against the antigen was detected
(Fairweather et al., 1990).

R esearch using S. typhimurium aroA SL3261 showed that it was possible to
generate an antibody response against an intracellular protein (Brown et al., 1987).
In this work, 8-galactosidase was used as the antigen and was found to produce a
circulating antibody response when adm inistered intravenously to mice.
Additionally, a delayed type hypersensitivity response was detected when purified 8galactosidase protein was injected into the footpads of previously immunised mice.

Attenuated S. typhimurium WR4017 has been used to develop vaccines against
Plasmodium spp. which cause malaria in a variety of animals. Oral immunisation of
mice with S. typhimurium transformed with the circumsporozoite gene was found to
induce protective cell-mediated immunity to sporozoites following challenge (Sadoff
et al., 1988).

Recently it has been shown that it is possible to obtain simultaneous protection from
more than one disease using Salmonella typhimurium aroA SL3261 mutants (Khan
et a l., 1994). In this study a modified vector (pTECH 1) contained the fragment C
from tetanus toxoid, a potent immunogen, fused to the 28kDa glutathione Stransferase (P28) from Schistosoma mansoni. Mice orally immunised with a single
dose o f the salmonella-tetanus-P28 construct produced antibodies against both
fragment C and P28 and were protected against challenge with virulent Salmonella
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typhim urium and tetanus toxin. Preliminary data suggests that this vaccine also
confers protection from challenge with schistosomula (Chatfield et al., 1995). This
research is the first to demonstrate that it is possible to confer protection against three
diseases using a single dose of a tri-valent oral vaccine.

N um erous heterologous antigens and antigenic epitopes from other parasites,
bacteria and viruses have been expressed in Salmonella spp., some of which are
included in Table 4.

Table 4. Heterologous antigens expressed in attenuated Salmonella.

Antigen

Organism

Host

Reference

C-fragment

Clostridium
tetani

S. typhimurium aroA,
S. typhimurium aroA aroD

(Fairweather, et al., 1990)
(Strugnell et al., 1990)

0 antigen

Vibro cholerae

S. typhi Ty21a

(Tacket et al., 1990)

O antigen

Shigella flexneri

S. typhi Ty21a

(Baron et al., 1987)

28kDa OMP

Nesseria
meningitidis

S. typhimurium aroA

(Tarkka et al., 1989)

M protein

Streptococcus
pyogenes

S. typhimurium aroA

(Poirier et al., 1988)

Nucleoprotein

Influenza A

S. typhimurium aroA

(Bao and Clements, 1991)

gpD

Herpes Simplex

S. typhimurium aroA

(Bowen et al., 1990)

VP7

Rotavirus SA11

S. typhimurium cya crp

(Salas-Vidal et al., 1990)

CSP

Plasmodium
falciparum

S. typhimurium WR4024

(Aggarwal et al., 1990)

gp63

Leishmania major

S. typhimurium aroA

(Yang et al., 1990)

B a cteria l

V ir a l

P a r a site s
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Table 4. Heterologous antigens expressed in attenuated Salmonella. (Continued)

Antigen

Organism

Host

Reference

LTB-HBsAg

Hepatitis B

S. dublin aroA
S. typhimurium cya crp asd

(Schödel et al., 1990)

Flagellin-M

Streptococcus
pyogenes

S. dublin aroA

(Newton et al., 1991)

E p ito p e s

Adapted from (O’Hagan, 1994).

1 .6 .7 Stability of Foreign Genes in S a lm o n ella spp.

A m ajor problem with the use of attenuated Salm onella spp. as a carrier of
heterologous proteins is to obtain stable expression of the foreign gene at levels
sufficient to provoke an appropriate immune response whilst ensuring expression is
controlled in such a way so that it is not deleterious to the host. Plasmids represent
the primary method used to express foreign genes in Salmonella. However, the use
of plasmids in antigen delivery systems has several drawbacks. Plasmid instability
represents a m ajor disadvantage when using these forms of expression systems,
which can lead to complete loss of the plasmid (O’Callaghan et al., 1988). The use
of high copy number plasmids or a strong promoter can result in the over-expression
of foreign proteins, a process that may be lethal to the bacterial cell (Shatzman et al.,
1983). Yet another disadvantage is the use of antibiotic selection. Although this
enables the maintenance of adequate levels of an unstable plasmid in vitro, the use of
antibiotic selection for human vaccines is undesirable.

A number of alternative strategies have been developed to overcome these problems
of plasmid instability and host viability. Integration of the recombinant antigen gene
into the bacterial chromosome represents a method used to obtain stable expression
o f foreign DNA. A system that uses a defective transposable element which stably
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inserts into the bacterial chromosome to express any gene o f interest has been
developed (Flynn et al., 1990). This delivery system, used in S. typhimurium aroA
has been shown to generate a cytotoxic T-lymphocyte response against foreign
antigens in mice. The drawback with this system is that only one copy of the gene is
expressed. A system using non-antibiotic resistant mini-transposons that allows the
cloning and stable insertion of foreign genes into the chromosome of Gram-negative
bacteria (Herrero et al., 1990) may also be useful for expression of foreign antigens
in Salmonella spp. An alternative approach is to utilise plasmids carrying a gene
essential for survival of the Salmonella in its host. In one system the asd gene, which
codes for aspartate B-semialdehyde dehydrogenase which is important in amino acid
biosynthesis and synthesis of bacterial peptidoglycan components, has been used.
This plasmid system was found to be very stable in Salmonella (Nakayama et al.,
1988).

1 .6 .8 Promoters for in vivo Expression

Unregulated high level expression of foreign proteins in Salmonella may be lethal to
the bacterium. This problem may be overcome using in vivo activated promoters that
allow the expression of the foreign gene only at a certain phase of its lifecycle or only
when the bacteria occupy a particular cellular compartment (Dougan, 1994). The
genetic regulation of certain genes in response to environmental signals such as
osmolarity, oxygen tension, the concentration of certain nutrients or intracellular
location, all represent potential avenues for the regulation of expression of foreign
gene products in Salmonella.

Plasmid stability has also been shown to be influenced to a large extent by the type of
prom oter used to express the foreign gene. Thus it would be desirable to use a
promoter that is efficiently regulated so as to be only active when bacteria enter the
host or when they interact with cells of the immune system. The nirB gene, which

encodes the E. coli NADH-dependent nitrite reductase is tightly regulated by its
prom oter in response to nitrite and by changes in the oxygen tension o f the
environment, becoming active under anaerobic conditions (Peakman et al., 1990).
Using this promoter, and altering the oxygen tension in fermentor systems, the high
level expression of P69 from B. pertussis has been attained (Oxer et al., 1991). This
prom oter has also been introduced into S. typhimurium aroA aroD vaccine strain
BRD509. In this study, the strain containing the nirB prom oter regulating the
expression of the immunogenic fragment C of tetanus toxin was found to be stable
and persisted in the tissues of immunised mice, whereas the strain containing a
plasmid with fragment C under the expression of a tac promoter was highly unstable
(Chatfield e t a l , 1992).

Another in vivo inducible promoter that has been characterised is the phoE promoter.
The PhoE protein is a pore-forming outer membrane protein (Benz and Bauer,
1988), and bacterial phosphate starvation results in the induction of the pho regulon.
The expression o f this prom oter has been found to be induced following 5.
typhim urium

invasion of eukaryotic cells. Thus this promoter is considered a

suitable candidate for regulated expression of foreign antigens to the immune system
(Janssen et al., 1995). In other work a method for the in vitro selection of promoters
activated by the intracellular milieu encountered by S. typhi following invasion of
eukaryotic cells has been developed (Staendner et al., 1995). This method may be
useful where the lack of a suitable animal model prevents analysis of disease
pathogenesis, and may provide insights into the topology of gene expression during
infection (Staendner et al., 1995).

1 . 6 . 9 A tte n u a te d Salm onella spp. as a C a rrie r of P ertu ssis A ntigens

Vaccines that provide both systemic and local protection in the respiratory tract may
offer better protection against disease and infection compared to the conventional
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whole cell vaccine or acellular vaccines derived from B. pertussis. Oral vaccination is
capable of stimulating immunity at distant sites such as the respiratory mucosa where
bacterial colonisation occurs. Pertussis vaccines administered orally would also
eliminate the risk o f blood borne diseases and increase vaccine availability in the
Third W orld where such vaccination would be in greatest demand. Researchers
investigating novel delivery systems for antigens of B. pertussis have investigated
the potential of several attenuated Salmonella strains.

In a previous study, recombinant SI subunit of PT was expressed in an attenuated
aroA mutant o f S. typhimurium, SL3261 and in the human typhoid vaccine strain
Salmonella typhi Ty21a (Walker et al., 1992). This recombinant strain was used to
orally immunise mice, and was found to induce IgG and IgA antibodies against the
SI subunit of PT in the lungs and IgG in the sera of vaccinated mice. In a similar
study, the S 1 subunit of PT was fused to the tetanus toxin fragment C and expressed
in the S. typhi vaccine strain CVD908; intranasally immunised mice engendered a
systemic anti-Sl IgG antibody response (Barry et al., 1996). However, to achieve
protective immune responses it would be desirable to have the entire PT holotoxoid
present, and not just SI or the B-oligomer (Nencioni et al., 1991). S. typhimurium
aroA has also been used to express a plasmid encoding FHA of B. pertussis
(Guzman et al., 1991a; Parker et al., 1990). In the latter study, IgG and IgA specific
antibodies were detected in lung washes and IgG in the sera of mice following oral
imm unisation. Similarly, P69, a surface localised antigen of B. pertussis was
expressed from the chromosome of the S. typhimurium aroA aroD vaccine strain
BRD509 and low level anti-P69 antibodies were detected only following a murine B.
pertussis aerosol challenge. This study also detected a CMI response in spleen cells
specific for P69 prior to challenge (Strugnell et al., 1992). Subsequent work was
aimed at constructing a vaccine strain capable of stimulating secretory, humoral and
CMI against P69. In this work P69 was found to be expressed at high levels in the
cytoplasm of BRD509 under the control of the nirB promoter. Although no anti-P69
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response was detected following oral immunisation of mice, priming of the immune
system was observed following subcutaneous boosting with purified P69 (Anderson
et al., 1996).

1 .7

Specific Aims

Although a great deal of research has been conducted on the development of acellular
vaccines against whooping cough, to date, all antigens of B. pertussis used for
vaccine development have been purified from this bacterium. Expression of wild
type PT in other bacterial species such as E. coli has previously been attempted
(Nicosia and Rappuoli, 1987), however factors such as differences in ribosomal
binding sites and promoter recognition resulted in a very weakly active promoter in
E. coli. Expression of these antigens in E. coli, for example would overcome
potential problems associated with the process of purification of antigens from
virulent B. pertussis. Such problems include the co-purification of other components
that m ay contam inate vaccines preparations. Additionally, B. pertussis is a
fastidious, slow growing organism, so expression of antigens in E. coli would
significantly increase yields whilst reducing vaccine cost. The first aim of this work
is to express the individual pertussis toxin subunits in E. coli, then to subsequently
construct a recombinant pertussis toxin operon capable of simultaneous expression
of the five PT subunit genes.

In addition to improving methods of vaccines preparation, research into the
development of novel vaccine delivery systems is still in progress. Oral vaccination
is capable of stimulating immunity at distant sites such as the respiratory mucosa
where colonisation occurs during B. pertussis infection. Such a vaccine delivery
system would increase vaccine acceptability and availability, thus contributing to the
immunisation of the infant population, who are susceptible to potentially fatal B .
pertussis infection. The development of oral immunisation systems will be facilitated
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by the expression of recombinant antigens in attenuated Salmonella spp. It may be
feasible and advantageous to use Salmonella aro mutants as carriers of PT subunits
for vaccine purposes. Studies to determine immune responses to these antigens will
also be undertaken using a murine model. Using this antigen delivery system there is
the potential to envoke strong local and mucosal immune response to all of the PT
subunits. The expression of the SI subunit of PT (Barry et al., 1996; W alker et al.,
1992), FHA (Guzman et al., 1991a; Molina and Parker, 1990; Parker et al., 1990)
and P69 (Anderson et al., 1996; Strugnell et al., 1992) in Salm onella spp. has
previously been achieved, this together with PT expression in Salmonella spp. may
constitute a more effective vaccine delivery system against pertussis when compared
to the current whole cell or acellular vaccines.
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2.

MATERIALS AND METHODS

2 .1

Bacterial Strains and Expression Plasmids

The bacterial strains used in this work are described in Table 5.

Table 5. Bacterial Strains used in this study.

Strain

Reference or Source

E. coli
JM109

Alacpro thi endA recA gyrA hsdR~ hsdM+

(Yanisch-Perron et al., 1985)

Sm F'traA 36 pro AB lactfZ M l 5 supE
CAG629

lorThtpRl 65 ::Tnl 0

C. Gross

876

pep-

R. Brownlie

EC538

J. McCarthy

YA21

(Mizushima and Yamada, 1975)

KS476

F-AlacX74 galE thi rpsL (strA)

J.E.G. Beckwith and K. Strauch

AphoA (PvuII) lpp5508 degP41 (APst-Kan)
H179

lorT

R. Brownlie

galE503 derivative of LB5000

B. Stocker

S. typhimurium
SL5283

hsdSB121 leu-3121
SL3261

aroA

(Hoiseth and Stocker, 1981)

SL7207

2337-65 (=WRAY) derivative

B. Stocker

HisG46 DEL407[aroA::TnlO {Tc-s}]
B. pertussis
Tohamal

(Kasuga et a l 1954)

The strains E. coli JM109 and E. coli CAG629 lon'htpR165::TnlO (C. Gross) were
used for construction o f expression plasmids and initial testing for recombinant PT
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subunit expression respectively. All E. coli and Salmonella strains were routinely
grown at 30°C in LB (Appendix A.vi) or on Z agar (Appendix A.v) (Walker and
Pemberton, 1988) supplemented with ampicillin (100 |ig/ml). B. pertussis was grown
on BG agar (Appendix A.iii) at 37°C.

The expression plasmids used in this work were pJLA506 (Walker et al., 1992) and
pC G V l (Guzman et al., 1994), both derivatives of pJLA503 (Schauder et al., 1987).
Plasmid pCGV 1 contains an alkaline phosphatase insertional inactivation screening
system and allows the export of recombinant proteins with a modified ß-lactamase
leader peptide.

2 .2

PCR Amplification of Pertussis Toxin DNA

2.2.1 Oligonucleotide Primers

The primers (Appendix H) used for PCR amplification (Sambrook et al., 1989) of PT
DNA are described in Table 6. Each PT subunit gene was PCR amplified using Taq
DNA polymerase (Boehringer Mannheim) from the native PT operon originating
from pTX42 (Locht and Keith, 1986) using primers synthesised on an Applied
Biosystems model 380B DNA synthesiser. All the 5' primers with the exception of
S4 were designed to incorporate the Ndel restriction enzyme site (underlined) within
the 5' sequence. The S4 5' primer, was designed to incorporate a N heI restriction
enzyme site and part of the modified ß-lactamase signal peptide. All 3' primers were
designed to incorporate an EcoRl restriction enzyme site (underlined) within the 3'
sequence. The corresponding PT subunit amino acid sequence is also shown whilst
the modified ß-lactamase sequence is italicised.

Table 6. Nucleotide sequence of the PCR primers used to amplify PT subunit DNA.
Primer

Sequencea

SI 5' Ndel

Met Arg Cys Thr Arg Ala lie
5'-GGCATATG CGT TGC ACT CGG GCA ATT-3’
NdeI

SI 3’ EcoRl

Tyr Ser Phe Stop
5'-TAT TCG TTC TAG ACC TGG GAA TTC CC-3’
3'-ATA AGC AAG ATC TGG ACC CTT AAG GG-5’

EcoRl
S2 5’ N de I

Met Pro lie Asp Arg Lys Thr
5’-GGCATATG CCG ATC GAC CGC AAG ACG-3’

Ndel
S2 3' EcoRl

Ser Leu Cys Stop
5'-TCC TTA TGC TGA GAC GCT GAA TTC CC-3’
3’-AGG AAT ACG ACT CTG CGA CTT AAG GG-5’
E coR l

S3 5’ N de I

Met Leu lie Asn Asn Lys Lys
5'-GGCATATG CTG ATC A AC A AC AAG A AG-3’
NdeI

S3 3' EcoRl

Ser He Cys Stop
5’-TCG ATA TGC TGA GCC GCC GAA TTC CC-3’
3'-AGC TAT ACG ACT CGG CGG CTT AAG GG-5’

EcoRl
Phe Cys Leu Pro Val Phe Ala
S4 5’ Nhel

5'-TT GCTAGC TTT TGC CTT CTT GTT TTT GCT

Nhel
Asp Val Pro Tyr Val Leu
GAC GTT CCT TAT GTG CTG GT 3'

S4 3’ EcoRl

Asp Cys Pro Stop
5'-GAT TGC CCC TGA AGG CGA GAA TTC CC-3'
T-CTA ACG GGG ACT TCC GCT CTT AAG GG-5'

EcoRl
S5 5' Ndel

Met His Thr He Ala Ser He
5'-GGCATATG CAT ACC ATC GCA TCC ATC-3’

Ndel
S5 3’ EcoRl

Tyr Cys Glu Stop
5'-TAT TGC GAA TGA ACC CTT GAA TTC CC-3'
T-ATA ACG CTT ACT TGG GAA CTT AAG GG-5'

EcoRl

a The nucleotide sequence of all 3' primers is given as the lower of the two nucleotide sequences
presented, the upper sequence represents the complementary sequence encoding the COOH end of the
PT subunit.
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2 .2 .2 PCR Protocol

The am plification o f the appropriate PT subunit DNA was perform ed in 0.5 ml
microcentrifuge tubes (Sarstedt) in a total volume of 100 p,l using a Hybaid Thermal
Cycler. The reaction mixture consisted of the following reagents listed in Table 7.

Table 7. The polymerase chain reaction mix.

Reagenti

Volume

Sterile gdf^O

78.5 pi

10 x PCR buffer*

10.0 pi

Final Concentration

1X

dATP

2.0 pi

200 pM

dCTP

2.0 pi

200 pM

dGTP

2.0 pi

200 pM

dTTP

2.0 pi

200 pM

5'Ndel primer

1.0 pi

0.2 pM

3'EcóKl primer

1.0 pi

0.2 pM

Taq DNA polymerase

0.5 pi

2.5 Units/100 pi

Experimental template

1.0 pi

1 ng/100 pi

f All PCR reagents except for Taq DNA polymerase and 10 x PCR buffer were obtained
from Perkin Elmer Cetus.
* Appendix B.xii.

The reagents were added to sterile tubes in the order listed in Table 7. Following
addition of reagents, 50 |il of mineral oil was overlayed and the solution spun at
15,000 g for 1 min in an Eppendorf centrifuge. The PCR reaction cycle performed to
amplify PT subunit genes is shown in Table 8.
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Table 8. PCR amplification cycle.

Step

Temperature

Time

1.1

95°C

5 min

1.2

50°C

1 min

1.3

70°C

1 min

2.1

95°C

1 min

2.2

50°C

1 min

2.3

70°C

1 min

Step

3.1

70°C

5 min

Step

4.1

37°C

holding temperature

Step

Step

x 1 cycle

x 35 cycles

x 1 cycle

Following PCR amplification, products were frozen at -20°C to facilitate the removal
of the mineral oil overlay which remained in a liquid form.

2 .3

Detection of Pertussis Toxin DNA

2.3.1 Agarose Gel Electrophoresis

Agarose gel electrophoresis (Sambrook et al., 1989) was performed using either the
Bio-rad Mini Sub™ DNA Cell or the Pharmacia Gel Electrophoresis Apparatus. DNA
samples to be electrophoresed where mixed with 0.2 volumes of agarose gel loading
dye (Appendix D.i) prior to electrophoresis. All agarose gels consisted of 1%
agarose/TAE. Gels were run at 50 V using 1 x TAE running buffer (Appendix B.i) for
between 1 and 2 h depending on the expected size of the DNA fragment.
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2.3.2 Determination of the Size of Restriction Fragments

Bacteriophage Lambda DNA digested with HindlU was included in each agarose gel
to provide reference fragments o f known molecular weight (Murray and Murray,
1975). The size of the restriction fragments was determined from a standard curve of
log molecular weight of reference fragment against relative mobility (Preifer, 1984).

2.3.3

Staining of Agarose Gels

Agarose gels were stained (Sambrook et al., 1989) in a solution consisting of 1 pg/ml
ethidium bromide for approximately 20 min. The gel was then viewed under ultra
violet light.

2 .4

Plasmid DNA Extraction

2.4.1 Qiagen Extraction

The extraction of plasmid DNA was undertaken in accordance with manufacturers
instructions as described in the following section. A bacterial culture was grown to
A595 0.5 in a 37°C shaker incubator. The culture was then centrifuged at 3,000 g for
15 min. The volumes o f buffer described in the following protocol are suitable for
midi preparations, and need to be adjusted according to the column size used. The
bacterial pellet was resuspended in 4 ml of buffer P I (Appendix E.i). Following
suspension, 4 ml o f buffer P2 (Appendix E.ii) was gently added to the mixture and
incubated at room tem perature for 5 min. After incubation, 4 ml of buffer P3
(Appendix E.iii) was added and mixed immediately by inverting the tube 6 times, then
the solution was incubated on ice for 20 min. Subsequently the solution was
centrifuged at 30,000 g for 30 min at 4°C and the supernatant was promptly removed.
If the supernatant was found to be turbid a second centrifugation at 30,000 g for 15
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min at 4°C was undertaken. A Qiagen-tip 100 was then equilibrated by the addition of
4 ml o f QBT (Appendix E.iv) buffer to the column, which was allowed to empty by
gravity flow. The supernatant was then applied to the column and allowed to empty by
gravity flow. The Qiagen tip was then washed with 2 x 10 ml of buffer QC (Appendix
E.v). Following the washes, the DNA was eluted from the column with 5 ml of buffer
QF (Appendix E.vi). To precipitate the DNA, 0.7 volumes (3.5 ml) of isopropanol
was added to the DNA eluant which was subsequently centrifuged at 15,000 g for 30
min, then the supernatant discarded. Finally the pellet was washed with 5 ml of 70%
ethanol, air dried for 5 min and redissolved in a suitable volume of gdH20 .

2.4.2

Small Scale Plasmid Extraction

Plasmid DNA was isolated by the method of Naumovski and Freidburg (1982). The
appropriate bacterial strain was grown overnight on agar plates with selection.
Individual colonies were then suspended in sucrose solution (Appendix E.vii) with 1
m g/m l lysozym e. The suspension was left at room tem perature for 30 min.
Subsequently, 0.3 ml of Triton X-100 solution (Appendix E.viii) was added and the
tube was inverted twice prior to a 15 min incubation at 65°C. The cell suspension was
then centrifuged for 30 min at 16,000 g. The supernatant was transferred to a clean
Eppendorf tube to which 10 drops of saturated phenol was added. The tube was
shaken vigorously and centrifuged for 15 min. The aqueous upper DNA layer was
removed carefully with a Pasteur pipette and added to a clean tube with 1 ml of diethyl
ether, this was then shaken and centrifuged for 1 min and the upper ether layer
discarded. The extraction with ether was then repeated. Following the extraction, 50
pi o f 3 M sodium acetate pH 7.0 was added prior to vortexing the solution. Ice cold
ethanol (1 ml) was mixed gently into the solution and the tube was placed at room
tem perature for 5 min. The solution was then centrifuged for 5 min, the ethanol
removed and the pellet air-dried for 10 min. The DNA pellet was suspended in 50 pi
gdH 20 to which 1 jul of 10 mg/ml RNase was added. The DNA suspension was
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incubated at 37°C for 30 min and vortexed prior to use. Following plasmid extraction
the D N A sam ples were digested using appropriate restriction enzym es then
electrophoresed on an agarose gel to determine whether the correct insert had been
cloned.

2.4.3

Extraction of DNA from Agarose Gels

Following the separation of DNA fragments by agarose gel electrophoresis, the DNA
was extracted and purified from the gel using the Bresa-Clean™ DNA purification kit
(Bresatec). Firstly, the band was excised from the gel and the volume of agarose by
weight was estimated. Three volumes o f Bresa-salt™ was then added to the tube
containing the DNA and this was incubated for 5 min at 55°C to dissolve the agarose.
Then, 5 (il plus 1 [il/|ig DNA of Bresa-bind™ was added and the suspension
incubated for 5 min at room temperature to bind the DNA to the resin. The suspension
was centrifuged for 5 seconds and the supernatant discarded. The pellet was washed
with Bresa-wash™ using a volume equivalent to the amount of Bresa-salt™ used
previously, and centrifuged for 5 seconds. The DNA was recovered by resuspending
the pellet in gdFkO using a volume twice that of the resin used. Following incubation
at 50°C for 5 min, the solution was centrifuged and the supernatant containing DNA
was recovered. The recovery rate and purity of the DNA fragment was then assessed
by agarose gel electrophoresis.

2 .5

Construction of Recombinant Clones

2.5.1

TA Cloning™ of PCR Products

The appropriate PCR fragments were cloned using the Invitrogen TA Cloning™ kit in
accordance with the manufacturers instructions.
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2.5.1.1

Plasmid pCR™II Vector Ligation Reaction

The ligation reaction was comprised of:
6 pi sterile H2 O
1 jil 10 x ligation buffer
2 |il plasmid pCR™II vector
1 |il PCR product
1 |ll T4 DNA ligase

This reaction mix was then incubated at approximately 12°C overnight.

2.5.1.2

TA Cloning™ Transformation

The tube containing the ligation reaction was spun briefly in an Eppendorf centrifuge
then placed on ice. Then, 2 |L il of 0.5 M B-mercaptoethanol was added to the
competent cells and mixed gently. A 1 jil sample of the ligation reaction was added
directly to the competent cells and the mixture placed on ice for 30 min. The mixture
was placed in a 42°C water bath for exactly 1 min then placed rapidly back on ice for 2
min. Next, 450 |ll of SOC medium (Appendix A.vii) was added to the transformation
mixture and the vial was shaken at 37°C for 1 h at 225 rpm. The mixture was then
placed on ice prior to plating out on X-gal agar plates (Appendix A.ii) containing 100
|ig/ml ampicillin for selection of the plasmid bearing colonies.

2.5.2

Restriction Endonuclease Digestion of DNA

All DNA restriction enzyme digestions (Sambrook et al., 1989) were undertaken
using 0.1-0.5 |Ltg of DNA, 2 jllI of the corresponding incubation buffer and 5-10 units
o f restriction endonuclease made up to a total volume of 20 |il with gdH20 . The
restriction enzym es used are shown in Table 9. Digestion was carried out by
incubation at 37°C for 1 h. The sticky ends formed by digestion were separated by
heating to 65°C for 5 min then placing the reaction mixture on ice for 5 min.
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Table 9. Restriction enzymes and buffers.

Enzymea

Recognition site

Buffo-

Bam H i

G GATCC

Tris-HCl, 10 mmol/1; NaCl, 100 mmol/1;
MgCl2, 5 mmol/1; ß-mercaptoethanol,
1 mmol/1; pH 8.0 (at 37°C).

Eco RI

G AATTC

Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1;
DTT, 1 mmol/1; pH 7.5 (at 37°C).

Hind m

A AGCTT

Tris-HCl, 10 mmol/1; NaCl, 100 mmol/1;
MgCl2, 5 mmol/1; ß-mercaptoethanol,
1 mmol/1; pH 8.0 (at 37°C).

Nde I

CA TATG

Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1;
DTT, 1 mmol/1; pH 7.5 (at 37°C).

N o tl

GC GGCCGC

Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1;
DTT, 1 mmol/1; pH 7.5 (at 37°C).

Pst I

CTGCA G

Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1;
DTT, 1 mmol/1; pH 7.5 (at 37°C).

Sal I

G TCGAC

Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1;
DTT, 1 mmol/1; pH 7.5 (at 37°C).

Xho I

C TCGAG

Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1;
DTT, 1 mmol/1; pH 7.5 (at 37°C).

(x 10)

a All restriction endonucleases were obtained from Boehringer Mannheim.

2.5.3

A lk aline P h o sp h ata se T re a tm e n t of V ector DNA

Alkaline phosphatase (AP) (Boehringer Mannheim) catalyses the removal of 5’phosphate residues from DNA. AP from calf intestine was used for this purpose to
enable efficient ligation with PT subunit DNA, following purification of the desired
DNA fragments. To 20 pi of DNA, 5 pi of 10 x AP dephosphorylation buffer
(Appendix B.ix) was added followed by 25 pi of gdH20 and 1 pi of AP. This mixture
was incubated at 37°C for 30 min. An additional 1 pi of AP was then added and the
mixture was again incubated at 37°C for 30 min. The enzyme was then inactivated at
65°C for 15 min.

Table 9. Restriction enzymes and buffers.

Enzyme3

Recognition site

Buffer

Bam HI

G GATCC

Tris-HCl, 10 mmol/1; NaCl, 100 mmol/1;
MgCl2, 5 mmol/1; ß-mercaptoethanol,
1 mmotyl; pH 8.0 (at 37°C).

Eco RI

G AATTC

Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1;
DTT, 1 mmol/1; pH 7.5 (at 37°C).

Hind III

A AGCTT

Tris-HCl, 10 mmol/1; NaCl, 100 mmol/1;
MgCl2, 5 mmol/1; ß-mercaptoethanol,
1 mmol/1; pH 8.0 (at 37°C).

Nde I

CA TATG

Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1;
DTT, 1 mmol/1; pH 7.5 (at 37°C).

Not I

GC GGCCGC

Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1;
DTT, 1 mmol/1; pH 7.5 (at 37°C).

Pst I

CTGCA G

Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1;
DTT, 1 mmol/1; pH 7.5 (at 37°C).

Sal I

G TCGAC

Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1;
DTT, 1 mmol/1; pH 7.5 (at 37°C).

Xho I

C TCGAG

Tris-HCl, 50 mmol/1; MgCl2 10 mmol/1;
DTT, 1 mmol/1; pH 7.5 (at 37°C).

(x 10)

a Ail restriction endonucleases were obtained from Boehringer Mannheim.

2.5.3

Alkaline Phosphatase Treatment of Vector DNA

Alkaline phosphatase (AP) (Boehringer Mannheim) catalyses the removal of 5’phosphate residues from DNA. AP from calf intestine was used for this purpose to
enable efficient ligation with PT subunit DNA, following purification of the desired
DNA fragments. To 20 jul of DNA (1.0 pg), 5 pi of 10 x AP dephosphorylation
buffer (Appendix B.ix) was added followed by 25 pi of gdH^O and 1 pi of A P. This
mixture was incubated at 37°C for 30 min. An additional 1 pi of AP (20 Units) was
then added and the mixture was again incubated at 37 °C for 30 min. The enzyme was
then inactivated at 65°C for 15 min.
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2.5.4

L ig a tio n of DNA w ith T4 L igase

The insert DNA and the vector DNAf were digested separately, then mixed together
and placed at 65°C for 1 min, then at 37°C for 10 min followed by 10 min at room
temperature. After this time 4 pi obligation buffer (B.viii) was added to the mixture,
followed by 1 pi of T4 DNA ligase (Boehringer Mannheim). The solution was then
mixed gently and incubated at 10°C overnight to allow ligation to proceed.

2.5.5

P re p a ra tio n o f C o m p eten t Cells

The appropriate bacterial strain was sixteen-streaked out on a Z agar plate (Appendix
A.v) and grown overnight at 37°C. The bacteria were then inoculated into 200 ml of
sterile LB and grown up in a shaking incubator at 37°C until the culture reached A56O
0.5 (3-4 h). The cells were then transferred into a sterile centrifuge tube and collected
by centrifugation at 4,500 g for 10 min at 4°C. The supernatant was discarded and the
bacterial pellet was placed on ice for 10 min. The cells were then resuspended in 100
ml of cold 0.1 M MgCl2. The centrifugation step was then repeated, then the cells
were resuspended in 10 ml of cold 0.1 M CaCl2. To obtain the optim um
transformation efficiency, the cells were left overnight prior to use.

2.5.6

T ra n sfo rm a tio n of B acterial Cells

Competent cells (200 pi) of the appropriate strain, were added to the ligation mixture
and resuspended. The mixture was placed on ice for 1 h, then incubated at 37°C for 5
min. Follow ing incubation, the mixture was spun for 1 min in an Eppendorf
centrifuge and the supernatant discarded (Cohen ct ¿2/., 1972). The pellet was
resuspended in 0.5 ml of LB and incubated for 1 h at 30°C. The transformation mix
was then plated out onto Z agar (Appendix A.v) with the appropriate selection and
incubated overnight at 30°C.
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2.5.4

Ligation of DNA with T4 Ligase

The insert DNA (1 pg) and the vector DNA (0.5pg) were digested separately, then
mixed together and placed at 65°C for 1 min, then at 37 °C for 10 min followed by 10
min at room temperature. After this time 4 pi of ligation buffer (B.viii) was added to
the mixture, followed by 1 jllI of T4 DNA ligase (1 Units) (Boehringer Mannheim).
The solution was then mixed gently and incubated at 10°C overnight to allow ligation
to proceed.

2.5.5

Preparation of Competent Cells

The appropriate bacterial strain was sixteen-streaked out on a Z agar plate (Appendix
A.v) and grown overnight at 37°C. The bacteria were then inoculated into 200 ml of
sterile LB and grown up in a shaking incubator at 37 °C until the culture reached A560
0.5 (3-4 h). The cells were then transferred into a sterile centrifuge tube and collected
by centrifugation at 4,500 g for 10 min at 4°C. The supernatant was discarded and the
bacterial pellet was placed on ice for 10 min. The cells were then resuspended in 100
ml of cold 0.1 M MgCl2. The centrifugation step was then repeated, then the cells
w ere resuspended in 10 ml of cold 0.1 M CaCl2. To obtain the optim um
transformation efficiency, the cells were left overnight prior to use.

2.5.6

Transformation of Bacterial Cells

Competent cells (200 pi) of the appropriate strain, were added to the ligation mixture
and resuspended. The mixture was placed on ice for 1 h, then incubated at 37°C for 5
min. Follow ing incubation, the mixture was spun for 1 min in an Eppendorf
centrifuge and the supernatant discarded (Cohen et al., 1972). The pellet was
resuspended in 0.5 ml of LB and incubated for 1 h at 30°C. The transformation mix
was then plated out onto Z agar (Appendix A.v) with the appropriate selection and
incubated overnight at 30°C.
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2.5.7

2.5.7.1

Selection of Potential Recombinant Clones

PCR Clones

Potentially recom binant clones (white colonies) were selected by the inability to
degrade X-gal after induction with IPTG and resistance to ampicillin (100 pg/ml).
Non-recombinant colonies appear blue on X-gal agar (Appendix A.ii).

2.5.7.2

Expression Vector Clones

Potentially recombinant clones were selected for on the basis of ampicillin resistance
(100 |Xg/ml) for pJLA506; in the case of pC G V l, XP agar (Appendix A.iv) which
differentiates between the ability (blue colonies) and the inability (white colonies) to
degrade the substrate XP supplemented with ampicillin (100 pg/ml) was used.

2.5.8

Fractionation of Bacterial Cells

Bacterial cells were fractionated to determine the subcellular location of processed PT
subunits according to the method of Comelis et al. (1982). Bacterial cultures were
grown overnight at 30°C, then used to inoculate 1 1 of LB. The culture was then
grown until an A56O0.8 was reached then the culture was temperature induced for 1 h
at 42°C. Following induction, the culture was centrifuged at 15,000 g for 5 min. The
pellet was then washed twice with an equal volume of 10 mM Tris-HCl (pH 8). The
pellet was resuspended in 0.5 volumes of fractionation buffer (Appendix B.vii) at
32°C for 30 min. The suspension was then centrifuged at 9,000 g for 15 min and the
pellet was subsequently resuspended in 0.25 volumes of ice cold gdH20 at 4°C for 30
min. The suspension was centrifuged at 10,000 g for 30 min at 4°C. Following
centrifugation, the supernatant containing the periplasmic fraction and the pellet
containing the cytoplasm ic fraction were retained. Intact cells were removed
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from the periplasmic and extracellular fractions using a Sartorius EasyFlow crossflow
system (0.2 pm cut-off). Fractions were then concentrated using a Sartorius
EasyFlow crossflow system (10,000 molecular weight cut-off).

2 .6

DNA Sequence Analysis of Recombinant Clones

The annealing o f prim er to the double-stranded tem plate and the subsequent
sequencing reactions (Sanger et al., 1977) were performed essentially as described in
the Pharmacia sequencing kit manual.

2.6.1 Annealing of Primer to Template
The concentration of template DNA was adjusted so that 32 pi contained 1.5-2 pg of
DNA. The double stranded template DNA was then denatured by the addition of 8 pi
of 2 M NaOH, the tube was vortexed and incubated at room temperature for 10 min.
Then, 7 pi of 3 M sodium acetate (pH 4.8) and 4 pi of gdH20 was added, along with
120 pi of 100% ethanol, The tube was then mixed and placed on ice for 15 min. The
DNA was then collected by centrifugation at 15,000 g for 15 min. The pellet was
subsequently washed with 70% ethanol, recentrifuged for 10 min and air dried prior
to being resuspended in 10 pi of gdH20. The concentration of the primer was adjusted
to 2.5-5 pM , such that 2 pi contained 5-10 pmol of primer. The primer (2 pi), and 2
pi o f annealing buffer (Appendix B.xi) was added to the 10 pi of denatured template
DNA. This mixture was vortexed, centrifuged briefly and incubated at 65°C for 5 min.
The mixture was allowed to slowly cool to room temperature over a period of at least
30 min.

2.6.2

Sequencing Reactions

For a short run (up to 500 nucleotides) 2.5 pi of the A mix-short, C mix-short,
’G’ mix-short and T mix-short respectively, were pipetted into corresponding tubes.
T7 DNA polymerase (Pharmacia) was then diluted on ice (1:4) using cold enzyme
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buffer (Appendix B.x). Next, 2 jitl o f the diluted T7 DNA polym erase, 3 pi of
labelling mix-dATP (Appendix B.xiii) and 1 |il of [alpha-32P]dATP (Bresatec), per
template were added to an Eppendorf tube placed on ice. This labelling mix was added
to the tem plate DNA mix and the components mixed gently then centrifuged and
placed at room temperature for 5 min. W hilst this reaction was in progress the four
tubes containing the sequencing mixes were warmed in a 37°C water bath for at least 1
min. After the labelling reaction had been incubated for 5 min, 4.5 pi of this reaction
was transferred into each of the four pre-warmed sequencing mixes, which were then
incubated at 37°C for 5 min. Following this incubation, 5.5 pi of the stop solution
(Appendix D.iii) was added to each tube and the tubes were placed on ice. A 3 pi
aliquot of each reaction was then transferred to a separate tube and the samples
denatured at 75°C for 2 min prior to being loaded onto the sequencing gel.

2.6.3

Sequencing Gel Set-up

The sequencing apparatus (IBI Base Runner) was set up and the sequencing gel
(Appendix C.iii) was poured and allowed to set for at least 3 h. The gel was then
placed in the buffer chamber and the chamber filled with 1 x TBE buffer (Appendix
B.ii), then pre-warmed for 1 h at 40 W prior to the samples being loaded. A 2 pi
aliquot of each sample was loaded onto the gel which was electrophoresed for the
appropriate time (3-6 h) at 40 W.

After the electrophoresis was complete, the gel was fixed by pouring a fixing solution
(Appendix G.iv) over the gel surface and soaking for approximately 20 min. The gel
was then transferred to a supporting sheet o f filter paper and covered with plastic
wrap, then dried using a vacuum gel dryer (Bio-rad). Once the gel was completely dry
it was placed in a film cassette and an appropriate sized sheet of X-ray film (Fuji) was
overlayed. The film was then left to expose for an appropriate time prior to
development. The autoradiograph was then placed in developer (Appendix G.v;
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Kodak) for 1 min, immersed in H2O, then placed in fixer (Appendix G.vi; Kodak) for
1 min, prior to being rinsed in H 2O. The DNA sequence was then read from the
autoradiograph.

2 .7

D etection o f P e rtu ssis T oxin S u b u n it E xp ressio n

2.7.1

T e m p e ra tu re In d u c tio n o f R eco m b in an t E xpression S tra in s

For induction o f PT subunit expression, overnight cultures were diluted to an A56O
0.4 and grown with aeration until an A56O 0.8 was reached then subsequently
temperature induced at 37°C, 39.5°C or 42°C for 1 h (Walker et al., 1992). A 1 ml
culture sam ple was taken follow ing tem perature induction. The sample was
centrifuged at 16,000 g for 5 min then the supernatant removed and the pellet
resuspended in 100 |il of 0.7% saline, to which an equal volume of PAGE sample
buffer (Appendix D.ii) was added. The sample was then placed in a boiling water bath
for 10 min prior to separation by PAGE.

2.7.2

S D S -P o ly acry lam id e Gel E le c tro p h o re sis (PA G E)

All resolving gels used to detect PT subunits were 15% acrylamide gels (Appendix
C.ii), with a 4% stacking gel (Appendix C.i). PAGE was undertaken according to the
method o f Laemmli (1970) using 1 x SDS-PAGE running buffer (Appendix B.iii).
For SDS-PAGE the Bio-rad Mini Protean II™ gel system was used. Gels were
electrophoresed at 150 V for approximately 2 h. Approximately 3.2 p,g of PT was
used as a positive control on SDS-PAGE gels. All SDS-PAGE gels also contained
low molecular weight markers (Bio-rad), in the case where the gel was subjected to
Western blot analysis, prestained low molecular weight markers (Bio-rad) were used.
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Kodak) for 1 min, immersed in H2O, then placed in fixer (Appendix G.vi; Kodak) for
1 min, prior to being rinsed in H 2O. The DNA sequence was then read from the
autoradiograph.

2 .7

Detection of Pertussis Toxin Subunit Expression

2.7.1

Temperature Induction of Recombinant Expression Strains

For induction of PT subunit expression, overnight cultures were diluted to an A560
0.4 and grown with aeration until an A 560 0.8 was reached then subsequently
temperature induced at 37°C, 39.5°C or 42°C for 1 h (Walker et al., 1992). A 1 ml
culture sam ple was taken follow ing tem perature induction. The sample was
centrifuged at 16,000 g for 5 min then the supernatant removed and the pellet
resuspended in 100 jul of 0.7% saline, to which an equal volume of PAGE sample
buffer (Appendix D.ii) was added. The sample was then placed in a boiling water bath
for 10 min prior to separation by PAGE.

2.7.2

SDS-Polyacrylamide Gel Electrophoresis (PAGE)

All resolving gels used to detect PT subunits were 15% acrylamide gels (Appendix
C.ii), with a 4% stacking gel (Appendix C.i). PAGE was undertaken according to the
method o f Laemmli (1970) using 1 x SDS-PAGE running buffer (Appendix B.iii).
For SDS-PAGE the Bio-rad Mini Protean II™ gel system was used. Gels were
electrophoresed at 150 V for approximately 2 h. Approximately 3.2 fig of PT was
used as a positive control on SDS-PAGE gels. All SDS-PAGE gels also contained
low molecular weight markers (Bio-rad), in the case where the gel was subjected to
Western blot analysis, prestained low molecular weight markers (Bio-rad) were used.
Within each SDS-PAGE gel equivalent amounts of protein were added to each lane. In
most instances, western blots were repeated to confirm expression or processing of
PT subunits.
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2.7.3

Coomassie Blue Staining of SDS-PAGE Gels

Proteins were visualised on SDS-PAGE resolving gels using Coomassie blue stain
(Appendix G.i). After development for 3 h, excess stain was removed by soaking in
destain (Appendix G.ii) for 4 h.

2.7.4

2.7.4.1

Antibodies Specific for PT Subunits

Polyclonal Antibodies

Polyclonal antibodies against a common epitope shared by S2 and S3, and an epitope
o f S5, were developed. Two 16mer synthetic peptides conjugated to diphtheria toxoid
were commercially synthesised: anti-S2/3 (RVHVSKEEQYYDYEDC) and anti-S5
(EDSPYPGTPGDLLELC) using a previously published method (Lee et al., 1980)
(Chiron Mimotopes). These two peptides were chosen on the basis of their antigenic
index and hydrophilicity (Kyte and Doolittle, 1982) determined using the Entrez
Database. Approxim ately 100 nmoles o f each peptide was resuspended then
emulsified with Freund’s complete adjuvant (Sigma) (1:2) in a total volume of 1 ml;
these em ulsions were used to subcutaneously immunise two New Zealand white
rabbits (day 0). On day 14 the rabbits were boosted as for day 0 except using
Freund's incomplete adjuvant (Sigma). On day 35 the rabbits were exsanguated by
heart puncture, then blood was collected and allowed to clot for 2 h at room
temperature. The clot was then displaced and serum collected by centrifugation at
3,000 g for 10 min.

2.7.4.2

Monoclonals Antibodies

M onoclonal antibodies used in this study were the following: anti-Sl, E19 derived
from culture supernatant (Walker et al., 1991a); anti-S4, 6DX3 derived from ascites
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fluid (Witviet et al., 1989); and anti-S5, 2D6 precipitated in (NFLO2SO4 (Bigio et al.,
1988).

2.7.5

Western Blot Analysis

2.7.5.1 Semi-dry Transfer

W estern blot analysis was undertaken according to a modified method of Burnette et
al. (1981). The stacking gel was removed from the resolving gel containing low
molecular weight prestained markers (Bio-rad) and cut down to minimal size. The gel
and an equivalent size sheet of nitrocellulose (0.45 Jim, Bio-rad) was equilibrated in
western transfer buffer I (Appendix B.iv) for 15 min. The same buffer was also used
to wet 10 sheets of filter paper cut to the same size. Five sheets of filter paper were
then placed on a Trans-Blot® SD Transfer Cell (Bio-rad), and air bubbles were
removed by gently rolling the surface with a glass rod after addition of each sheet. The
nitrocellulose was then placed on top of the filter paper and again air bubbles were
removed. The gel and the 5 remaining sheets of filter paper were then added. The
transfer apparatus was run at 15 V for 20 min.

2.7.5.2

Wet Transfer

The gel and a sim ilar size piece of Immobilon™ -P, PVDF (M illipore) were
equilibrated in western transfer buffer II (Appendix B.v) for 20 min. The Bio-rad
M ini Trans-Blot® Cell was then assembled and electrophoresis undertaken at 100 V
for 1 h at 4°C.
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2.7.5.3

Blocking and Western Blot Development

Following transfer, the nitrocellulose was blocked using low fat milk (0.1%), made
up to 10% in PBS (Appendix B.vi) for 1 h on an orbital shaker. After blocking, the
solution was discarded and the first antibody diluted 1:500 in PBS was added, and
rocked gently for 1 h at room temperature. The first antibody was removed and the
m em brane washed in PBS (3 x 10 min). The final wash was discarded then the
second antibody (goat anti-mouse or anti rabbit IgG, HRP conjugate; Bio-rad) diluted
1:500 in PBS was added and rocked for 1 h at room temperature. The membrane was
again washed in PBS (3 x 10 min). The colour development solution (Appendix
G.vii) was added to the membrane and it was left to develop until bands became
visible. The membrane was then removed from the colour development solution,
washed with gdibO and allowed to dry.

2.8.

Tissue Culture Methods and in vitro Intracellular Survival
A ssays

Intracellular survival assays were perform ed by Dr C. Guzman (GBF-National
Research Centre for Biotechnology, Braunschweig, Germany). Briefly, the human
intestinal epithelial cell line Henle 407 (ATCC CCL-6) was maintained in DME with
10% FCS, 5 mM glutamine and 1 mM pyruvate, in an atmosphere containing 5% CO2
at 37°C. Trypsinized cells were seeded at a concentration o f approximately 2 x 105
cells in tissue culture plates (12 by 4.5 cm2; Flow). These were incubated for 18 to 24
h and then washed three times in PBS (pH 7.4) (Appendix B.vi). For infection of
m onolayers, bacteria in the exponential growth phase were harvested by
centrifugation, resuspended to a density of 108 CFU/ml in DME, overlaid onto the
monolayer o f cells, and incubated for 45 min at 37°C with 5% CO2. Unattached and
loosely attached bacteria were removed by washing the monolayers three times with
PBS. For invasion assays, DME containing gentamicin (100 Jig/ml) was then added;
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this concentration o f gentamicin killed extracellular bacteria and thereby prevented any
reinfection o f cells. Monolayers were incubated for 4 h or 24 h then washed three
tim es with PBS. The number o f invading bacteria was determined by lysing the
eukaryotic cells with the addition of 1 ml of 1% Triton X-100 (vol/vol) to each well
and calculating the viable counts on Z agar plates (Appendix A.v).

2 .9

Assessment of Antibody Response and Protectiveness of
Pertussis Toxin Subunit Producing Strains

2.9.1 Mouse Immunisation and Sample Collection

Six- to eight-week-old female BALB/c mice were immunised and caged separately in
groups o f up to six. The groups were immunised with one dose on day 0 and boosted
with identical doses 30 and 40 days later. The mice were sacrificed 10 days after the
last booster, and the samples were collected. For immunisations, S. typhimurium
aroA SL3261 and SL7207 strains were grown and induced at 37°C or 39.5°C for 1 h,
as previously described (2.7.1). Once the appropriate optical density had been reached
the cells were recovered by centrifugation and resuspended in an equal volume of
sterile PBS and 3% sodium bicarbonate to approximately 1 x 10^ CFU for oral
immunisation. Mice were anaesthetised in an enclosed chamber using anaesthetic
ether. The cell suspension (0.1 ml) or PBS was administered orally by gavage tube.
For the positive control, 0.1 ml of (100 Jig/ml) gluteralderhyde detoxified PT (Munoz
et a l., 1981) in 20 mM PBS 500 mM NaCl (pH 7.6) was adm inistered
intraperitoneally.

M ice were sacrificed by cervical dislocation, then exsanguinated by cutting the
brachial artery, and serum was separated and stored at -20°C. After exsanguination the
trachea was isolated and exposed. Lung washes were collected after pertracheal
cannulation and gentle washing with 0.7 ml of ice-cold PBS containing 2 mM
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phenylmethylsulfonyl fluoride as a protease inhibitor. Lung washes were centrifuged
at 3,000 g for 5 min to remove debris and stored at -20°C.

2.9.2

Enzyme Linked Immunosorbent Assays (ELISAs)

For the determ ination of subclass specific antibodies against PT in sera and lung
washes, ELISAs were performed as follows: Titertek 96-well plates were coated with
pertussis toxoid (kindly supplied by R. Rappuoli) diluted in 0.1 M NaHCC>3 (pH 9.6)
(60 ng in 50 jllI per well) and incubated at 4°C overnight. The wells were blocked with
100 j-il o f 10% FCS in PBS for 2 h at 37°C. Plates were subsequently washed three
times with PBS containing 0.05% Tween 20, and 100 ]il of serum samples (diluted
1:50) or lung washes (diluted 1:5) in 10% FCS in PBS was added to each well. After
2 h at 37°C, the plates were again washed, and 100 |il of HRP conjugated rabbit anti
mouse antibody for IgG or IgA heavy chains (Kirkegaard and Perry Laboratories)
diluted 1:2,000 and 1:400 respectively in 10% FCS in PBS was added to each well
and incubated for 2 h at 37°C. The plates were again washed and then developed by
the addition of 100 pi of substrate solution (Appendix G.iii). After an appropriate time
at room temperature, the reaction was stopped by the addition of 50 (il of 2 M H2SO4
and the A450 was determined with a Bio-rad Model 3550 microplate reader. Each
serum or lung wash sample was individually assayed, and control PBS immunised
m ice were used as the blank for ELISA reading. The titre was expressed as the
reciprocal o f the highest dilution of test serum or lung wash that gave an absorbance
reading twice that of background. The background absorbance was determined using
PBS immunised mice sera. Western blot analysis of sera from vaccinated mice was
perform ed as described above to determine the subunit specificity of the antibody
response. Sera from mice immunised with pertussis toxoid was diluted 1:1,000 whilst
all other sera from vaccination experiments was diluted 1:16.
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2.9.3

Intracerebral Challenge

The Kendrick test (Kendrick et al., 1947) was used to test the efficacy of experimental
pertussis vaccines and was perform ed at the Therapeutic Goods Administration,
Sym onston, A ustralia. Five week old fem ale ARC Swiss fem ale m ice were
immunised and caged separately in groups of 16. The mice were anaesthetised using
0.2 m l o f a 6 m g/m l solution of Nembutal (Boehringer Ingelheim) administered
intraperitoneally. The mice were then orally immunised with one dose o f the cell
suspension or PBS on day 0, then challenged intracerebrally with 20 fil o f 10"3-3 of
B. pertussis 18-323 (TGAL passage 18323 L6dH4, 2nd passage B5/6-7/6 1982)
using a Hamilton syringe on day 14. The mice were then held for 14 days then the
number o f survivors were counted. Mice that died within 48 h following challenge
were excluded from the assay. The reference vaccine used for this assay was the
A u stralian standard fo r pertussis, SS546 (CSL, A ustralia) adm inistered
intraperitoneally (C dose, which consists of killed B. pertussis cells, and is formulated
to give 50% survival after challenge).

2.10.1

Statistical Analysis

Antibody responses for specific isotypes between treatment groups within the same
ELISA series were compared using a Tukey multiple comparison test for unequal
sample sizes as described by Zar (1984).
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3.

RESULTS

3 .1

Expression of Pertussis Toxin in E. coli

The expression o f PT in E. coli w o u ld represents a m ajor step towards the
development of new generation recombinant pertussis vaccines. Using E. coli as a
host it may be possible to obtain higher yields of PT with less expense compared to
expression in Bordetella spp. However, there has been little success in expressing
native PT subunits or holotoxin in E. coli from B. pertussis promoters. This is
probably due to differences in the ribosomal binding sites and promoter recognition
sequences between E. coli and B. pertussis (Nicosia et al., 1987). In one notable
study (Burnette et al., 1988a), all the PT subunits apart from S4 were expressed in
E. coli with their native leader sequences attached; the S 1 subunit was the only
subunit completely processed. The replacement of the native leader sequence with a
methionine initiation codon resulted in the production of mature protein, in the form
of insoluble inclusion bodies for the five PT subunits. The work presented in this
section represents a novel method of overcoming the difficulties encountered in the
expression o f foreign proteins in E. coli, and shows that a recombinant PT operon
can be expressed in this host whilst still using, in the most part, native leader
sequences. PT subunit expression in E. coli has been achieved by utilising a cloning
strategy that enables the foreign proteins to be expressed using bacteriophage
Lambda P r and P l promoters and an E. coli ribosomal binding site located upstream
of the cloning site.

3 . 1 . 1 PCR Amplification of the Pertussis Toxin Genes

The individual PT subunits genes encoding SI to S5 were amplified from the native
PT operon (Locht and Keith, 1986) using primers that incorporated a 5' NdeI site
and a 3' E coR l site in the oligonucleotide sequence (Table 6). All PT subunit genes
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shown in Figure 8 were amplified without the replacement of their native leader
sequences.
1
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Figure 8. Agarose gel electrophoresis of PCR amplified PT subunit genes. Lane 1, SI; lane 2, S2;
lane 3, S3; lane 4, S4; lane 5, S5. Lane 6 contains Lambda HindlU molecular weight markers, the
size of which, in base pairs, are indicated by arrows.

3 .1 . 2

E x p ressio n of th e In d iv id u a l P ertu ssis Toxin S ubunit G enes in
E. coli C A G 6 2 9

Following PCR amplification, the individual PT genes were cloned into the PCR
cloning vector pCR™II (2.5.1.1) via use of the A overhang generated by Taq DNA
polymerase during PCR amplification. Figure 9 represents the strategy used to clone
PT subunit genes into pCR™II; in this case the SI subunit gene was cloned into
pCR™II.
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All PT subunit gene PCR products were then subcloned into the expression vector
pJLA506 using the restriction enzymes Ndel and EcoRl (Figure 10A). Subsequently
it was found that the S4 subunit was not expressed from pJLA506 in E. coli
CAG629 (result not shown). Thus, in the case of the S4 subunit gene a new 5'
primer was synthesised. This primer encoded an NheI restriction enzyme site and the
COOH-terminus of a modified 6-lactamase leader sequence (Table 6) which, when
subcloned into the vector pC G V l with N he I and E co R l restriction enzymes,
reconstituted the modified 6-lactamase signal peptide (Guzman et al., 1994) (Figure
10B).

The expression plasm ids containing the individual PT subunit genes were
transformed (2.5.6) into the protease deficient E. coli CAG629 (Table 5). A protease
deficient E. coli strain was used to prevent the possible degradation of PT subunits
following induction of expression. After induction (2.7.1) of mid log-phase cultures
at 42°C for 1 h, whole cell extracts were subjected to SDS-PAGE (2.7.2).
Electrophoresed proteins were visualised by staining the gel with Coomassie blue
(2.7.3) or W estern blot analysis (2.7.5). Recombinant S I, S2, S3, S4 and S5 were
detected at levels significantly higher than those found in B. pertussis Tohama I
(Figure 11A-F). In contrast to a previous study (Burnette et al., 1988a), each subunit
was at least partially processed as assessed by analysis of the molecular weights of
immunoreactive gene products suggesting that each subunit is being secreted into the
E. coli periplasm.

3 . 1 . 3 G ro w th R ate of E. coli CAG629 S tra in s E xpressing the
In d iv id u a l P e rtu ssis Toxin S ub u n its follow ing T e m p e ra tu re
In d u c tio n

The possibility that the expression of foreign proteins in E. coli CAG629 may be
detrimental to cell physiology was addressed by assessing the growth rate of strains
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All PT subunit gene PCR products were then subcloned into the expression vector
pJLA506 using the restriction enzymes NdeI and EcoRl (Figure 10A). Subsequently
it was found that the S4 subunit was not expressed from pJLA506 in E. coli
CAG629 (result not shown). Thus, in the case of the S4 subunit gene a new 5’
primer was synthesised. This primer encoded an Nhel restriction enzyme site and the
COOH-terminus of a modified 13-lactamase leader sequence (Table 6) which, when
subcloned into the vector pC G V l with N h e l and E co R l restriction enzymes,
reconstituted the modified 13-lactamase signal peptide (Guzman et al., 1994) (Figure
10B). This vector had previously successively been used to express and secrete the
serotype 2 fimbriae in E. coli (Walker et al., 1990).

The expression plasm ids containing the individual PT subunit genes were
transformed (2.5.6) into the protease deficient E. coli CAG629 (Table 5). A protease
deficient E. coli strain was used to prevent the possible degradation of PT subunits
following induction of expression. After induction (2.7.1) of mid log-phase cultures
at 42°C for 1 h, whole cell extracts were subjected to SDS-PAGE (2.7.2).
Electrophoresed proteins were visualised by staining the gel with Coomassie blue
(2.7.3) or W estern blot analysis (2.7.5). Recombinant S I, S2, S3, S4 and S5 were
detected at levels significantly higher than those found in B. pertussis Tohama I
(Figure 11A-F). In contrast to a previous study (Burnette et al., 1988a), each subunit
was at least partially processed as assessed by analysis of the molecular weights of
immunoreactive gene products suggesting that each subunit is being secreted into the
E. coli periplasm.

3 . 1 . 3 Growth Rate of E. coli CAG629 Strains Expressing the
Individual Pertussis Toxin Subunits following Temperature
Induction

The possibility that the expression of foreign proteins in E. coli CAG629 may be
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Figure 9. A schematic representation o f cloning of the SI subunit gene into pCR™n. The PT
subunit gene (S I) was amplified by PCR using the SI 5' Ndel and 3' £c<?RI primers, then ligated
into the cloning vector pCR™II. PT subunit genes SI to S5 (open arrows) and the PT promoter
(filled arrow) are indicated. The pCR™II cloning vector contains the lacZ alpha fragment and
multiple cloning site (open arrow), FI origin (cross hatched box), pBR322 origin (ori), Kanamycin
(Kan) and Am picillin (Amp) resistance genes (open boxes). The direction o f transcription is
indicated either by thin arrows or the orientation of open arrows. Plasmids are not drawn to scale,
and only relevant restriction sites are shown.
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Amp

Figure 10. Plasmid vectors for the expression o f single PT subunits. Expression vector (A),
pJLA506 was used to express the PT subunit genes SI, S2, S3 and S5 (open arrows) whilst (B),
pC G V l, a derivative of the former which contains the NH 2 -terminal of the modified 8-lactamase
signal sequence (filled box) was used to express the S4 subunit (open arrow). Both expression
plasmids contain the Lambda promoters Pr and Pl (filled arrows), atpE ribosomal binding site
(between the Xhol and Ndel restriction enzyme sites of the vectors), bacteriophage fd transcriptional
terminator (cross-hatched box), ampicillin resistance gene and Lambda c l ^ 57 temperature sensitive
represser gene (open boxes). Plasmid pCGVl also contains an alkaline phosphatase gene (open
box). The direction of transcription is given either by thin arrows or the orientation of open arrows.
Plasmids and PT subunit genes are not drawn to scale and only relevant restriction enzyme sites are
shown.

66

A
1 2

c

B
3

4

1 2

3

4

1 2

3

4

Figure 11. Expression of individual PT subunits in E. coli CAG629 compared with PT expression
in B. pertussis Tohama I. In all panels lane 1 contains CAG629 (pJLA506) except panel D which
contains CAG629 (pCGVl). Lane 2 contains the recombinant PT expression plasmid in CAG629:
panel A, SI; panel B, S2; panel C, S3; panel D, S4; panel E, S5. In all panels lane 3 contains B.
pertussis Tohama I and lane 4 contains purified PT. Panel F shows the Coomassie stained gel
corresponding to panel A. The filled arrowheads indicate processed PT subunits whilst the open
arrowheads indicate PT subunit pre-proteins.
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harbouring the individual PT subunits following temperature induction. The growth
rate o f E. coli CAG629 either alone or harbouring the expression plasmid pJLA506
remained the same and was not adversely affected by temperature induction at 42°C
(2.7.1) (Figure 12A). However all strains harbouring PT expression plasmids, apart
from S I, showed a decrease in growth rate com pared to vector only strains
following temperature induction at 42°C (Figure 12B-F).

3 . 1 . 4 C o n stru c tio n o f a S ynthetic P e rtu ssis T oxin O p ero n

Since the expression of all five PT subunits in E. coli CAG629 proved successful,
the next goal towards recombinant PT production in E. coli was to express the PT
subunits simultaneously in this host, using a single expression vector. Thus, a
stepwise cloning strategy for the construction of a synthetic PT operon was
developed by employing a pair of restriction enzymes that generate identical sticky
ends after restriction enzyme digestion of DNA. The expression vectors pJLA506
and pC G V l both contain a unique X h o l site adjacent to and 5' of the vector
ribosome binding site. Each plasmid also contains a Sail site 3' and adjacent to the
stop codon. In this work, for instance, the S5 subunit was cloned as a X hol/Sall
fragment into the X hol site of the S 1 expression plasmid; a recombinant operon was
formed where both subunits are in the same orientation. As Sail and Xhol restriction
fragments have the same "sticky ends” they ligate together, disrupting the recognition
sequence of both enzymes. Thus the S5+S1 operon produced, once again contains a
single X h o l restriction site (Figure 13). Repetition of this cloning process has
yielded a synthetic operon containing the 5 PT subunits.
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harbouring the individual PT subunits following temperature induction. The growth
rate of E. coli CAG629 either alone or harbouring the expression plasmid pJLA506
remained the same and was not adversely affected by temperature induction at 42°C
(2.7.1) (Figure 12A). However all strains harbouring PT expression plasmids, apart
from S I, showed a decrease in growth rate compared to vector only strains
following temperature induction at 42°C (Figure 12B-F). The growth rate of E.coli
CAG 629 expressing pJLA506 was equivalent to that of E. coli CAG629 (pCGVl)
(results not shown).

3 . 1 . 4 Construction of a Synthetic Pertussis Toxin Operon

Since the expression of all five PT subunits in E. coli CAG629 proved successful,
the next goal towards recombinant PT production in E. coli was to express the PT
subunits simultaneously in this host, using a single expression vector. Thus, a
stepwise cloning strategy for the construction of a synthetic PT operon was
developed by employing a pair of restriction enzymes that generate identical sticky
ends after restriction enzyme digestion of DNA. The expression vectors pJLA506
and pC G V l both contain a unique X h o l site adjacent to and 5' of the vector
ribosome binding site. Each plasmid also contains a Sail site 3' and adjacent to the
stop codon. In this work, for instance, the S5 subunit was cloned as a X hol/Sall
fragment into the Xhol site of the S 1 expression plasmid; a recombinant operon was
formed where both subunits are in the same orientation. As Sail and Xhol restriction
fragments have the same "sticky ends" they ligate together, disrupting the recognition
sequence of both enzymes. Thus the S5+S1 operon produced, once again contains a
single X h o l restriction site (Figure 13). Repetition of this cloning process has
yielded a synthetic operon containing the 5 PT subunits.
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Figure 12. Growth curves o f E. coli CAG629 expressing the individual PT subunits following
temperature induction at 42°C. Panel A, CAG629 and CAG629 (pJLA506); panel B, CAG629
(pJLA506) and CAG629 (pJLA506 SI); panel C, CAG629 (pJLA506) and CAG629 (pJLA506 S2);
panel D, CAG629 (pJLA506) and CAG629 (pJLA506 S3); panel E, CAG629 (pJLA506) and
CAG629 (pCGVl S4); panel F, CAG629 (pJLA506) and CAG629 (pJLA506 S5). The time of
induction is indicated by an arrow.
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Figure 13. Construction of plasmids for the expression of multiple PT subunits. Each atpE
ribosomal binding site and PT subunit gene flanked by 5’ Xhol and 3' Sail restriction enzyme sites
is indicated as an open arrow. The 6-lactamase leader sequence (filled box) fused to the mature S4
subunit is also indicated. Both expression plasmids contain the Lambda promoters Pr and Pl (filled
arrows), bacteriophage fd transcriptional terminator (cross-hatched box), ampicillin resistance gene
and Lambda c l^ 857 temperature sensitive represser gene (open boxes). The direction of transcription
is given either by thin arrows or the orientation of open arrows. Plasmids are not drawn to scale, and
only relevant restriction sites are shown.
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3 . 1 . 5 Simultaneous Expression of Pertussis Toxin Subunits in E. coli

Using the cloning strategy described previously, a number of plasmid constructs
possessing different combinations of PT subunit genes were assessed for PT subunit
expression in E. coli (Figure 15). To investigate expression, the following E. coli
strains were used: CAG629, EC538, H179, KS476, YA21 and 876. These host
strains were chosen since they possess genotypes that favour the expression of
foreign proteins (Table 5). In this cloning strategy, for instance, the S2 gene was
cloned 5* of S I, resulting in pDP13, which was found to be capable of expression of
S2 and SI in the six E. coli strains investigated. The S5 gene was then cloned 5' of
S2 in pDP13 to produce pDP15 (S5+S2+S1). In this case however, expression of
the three PT genes was variable, depending on the E. coli host; SI (Figure 14, lane
6), S2 and S5 (result not shown) were expressed in EC538, H179, KS476, YA21
and 876, but not in CAG629. The addition of S4, 5' of S5 in pDP15 resulted in
pDP17 (S4+S5+S2+S1). Variable expression of PT subunit genes was also
observed in this construct; the addition of S4 abolishing expression of the proximal
S5 subunit in all six E. coli strains, whilst SI (Figure 14, lane 7) and S2 (result not
shown) were expressed in EC538, and all other E. coli strains except CAG629
(result not shown). Another series of constructs were produced, whereby S5 was
cloned 5’ of S 1, generating pD Pl 1; S 1 (Figure 14, lane 4) and S5 (result not shown)
were expressed by this construct in E. coli EC538 and in the other E. coli strains.
The addition o f S2 5’ of S5 in p D P ll produced pDP18 (S2+S5+S1); in this
construct SI and S2 were expressed, whilst S5 was not detected, which was the
case for all the E coli strains investigated (results not shown). The replacement of S2
with S4 in pDP18 generated pDP12 (S4+S5+S1). In this construct S4, S5 and SI
were expressed in all six E. coli strains. Two similar constructs, pDP14 (S2+S3)
and pDP19 (S3+S2), were also produced, both capable of expressing S2 and S3 in
all E. coli strains. The DNA fragments containing S2 and S3 in pDP14 and pDP19
were then cloned 5’ of S4 in pDP12 resulting in pDP16 (S2+S3+S4+S5+S1) and
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pDP2Q (S3+S2+S4+S5+S1) respectively, all five PT subunit genes were expressed
in both of these construct in all six E. coli strains investigated (Figure 15).
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Figure 14. Representative Western blot analysis of SI subunit expression in E. coli EC538. Lane 1
contains the E. coli CAG629 (pJLA506 SI); lane 2, E. coli EC538 (pJLA506); lane 3, E. coli
EC538 (pJLA506 SI); lane 4, E. coli EC538 (pD Pll); lane 5, E. coli EC538 (pDP13); lane 6, E.
coli EC538 (pDP15); lane 7, E. coli EC538 (pDP17); lane 8 contains purified PT. The SI subunit
of PT was detected using anti-Sl antiserum. The filled arrowhead indicates processed SI subunit
protein, whilst the open arrowhead indicates SI subunit pre-protein.

72

Expression of individual subunits
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Figure 15. Simultaneous expression of multiple PT subunits in E. coli. PT subunit gene constructs
shown with their corresponding ability to express subunit proteins in E. coli. The wild type PT
operon is not expressed in E. coli (Nicosia et al., 1986) (shaded arrows). Recombinant PT subunit
genes are given as open arrows; expression is indicated by a plus symbol (+) whilst no detectable
expression is indicated by a minus symbol (-). For certain constructs, PT subunit expression was
detected in all E. coli strains tested except E. coli CAG629 (+/-).

The plasmids (pDP20 and pDP16) harbouring the five PT subunits differed only in
the orientation o f the S2 and S3 subunit genes. It was noted that in pDP20
expression of the S2 subunit was reduced compared to expression of this subunit in
pDP16 (result not shown), thus pDP16 was used for subsequent work. Western blot
analysis o f PT subunit expression in E. coli KS476 containing the synthetic PT
operon (pDP16), indicated that S4 and S5 were completely processed, SI was
partially processed, whilst the majority of S2 and S3 remained unprocessed (Figure
16A-D).
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Figure 16. Western blot analysis of PT subunit expression in E. coli KS476 containing pDP16. In
all panels lane 1 contains KS476 (pJLA506), except in panel C which contains KS476 (pCGVl),
whilst lane 2 contains the recombinant single PT subunit expression plasmid in KS476: panel A,
SI; panel B, S2; panel C, S4; panel D, S5. Panel B lane 2* contains KS476 bearing the S3 subunit
expression plasmid. Lane 3 contains KS476 (pDP16). Lane 4 contains purified PT. PT subunits
were detected using specific antiserum: panel A, anti-Sl; panel B, anti-S2 and S3; panel C, anti-S4,
and panel D, anti-S5. The filled arrowheads indicate processed PT subunits whilst the open
arrowheads indicate PT subunit pre-proteins.

3 . 1 . 6 DNA S equence A nalysis of pD P16

The recombinant PT operon (pDP16) constructed in this study was confirmed by
DNA sequence analysis (2.6; Sanger et al., 1977) The DNA sequence o f the
synthetic PT operon of pDP16 is shown in Figure 17.

Xhol
CTCGAG XAATT*TAClr AA CATTA rT&CGTTTTAACTGAAACAAACTQQAQACTCAT

ATG CCG ATC GAC C GC AAG ACG CTC TGC CAT CTC CTG T CC
M et Pro H e A sp A r g L y s Thr Leu C y s HI n [.Oil U n i

GTT CTG CCG TTG GCC CTC CTC GGA TCT CAC GTG GCG CGG g c c T t c c ACG CCA GGC ATC GTC ATT CCG CCG CAG GAA CAG ATT ACC
L eu P ro L eu A l a L eu L eu G l y S e r H i s V a l A l a A rg A l a S e r T hr Pro G l y H e V a l H e Pro Pro G in G lu G in l i e T hr
CAG CAT GGC AGC C CC TAT GGA CGC TGC GCG AAC AAG A CC CGT GCC CTG ACC GTG GCG GAA TTG CGC GGC AGC GGC GAT CTG CAG
G in H i s G l y S e r Pro T y r G l y A rg C y s A l a A sn L y s T hr A r g A l a L eu T hr V a l A l a G l u Leu A rg G l y S e r G l y A sp Leu G in
GAG TAC CTG CGT CAT GTG ACG CGC GGC TGG TCA ATA IT T GCG CTC TAC GAT GGC A CC TAT CTC GGC GGC GAA TAT GGC GGC GTG
G l u T y r L eu A r g H is V a l T hr A rg G l y T rp S e r M et Phe A l a Leu T y r A sp G l y T h r T y r Leu G l y G l y G lu T yr G l y G l y V a l
ATC AAG GAC GGA ACA C CC GGC GGC GCA TTC GAC CTG AAA ACG ACG TTC TGC ATC ATG A CC ACG CGC AAT ACG GGT CAA C CC GCA
l i e L y s A s p G l y T hr Pro G l y G l y A l a Phe A s p Leu L y s T hr T hr Phe C y s H e M et T h r T hr A rg A sn Thr G l y G in P ro A la
ACG GAT CAC TAC TAC AGC AAC GTC ACC GCC A CT CGC CTG CTC TCC AGC ACC AAC AGC AGG CTA TGC GCG GTC TTC GTC AGA AGC
T h r A s p H i s T y r T y r S e r A sn V a l T hr A l a T h r A r g Leu Leu S e r S e r T hr A sn S e r A r g Leu C y s A la V a l Phe V a l A rg S e r
GGG CAA C CG GTC ATT GGC GCC TGC A CC AGC CCG TAT GAC GGC AAG TAC TGG AGC ATG TAC AGC CGG iTTG CGG AAA ATG CTT TAC
G l y G in P r o V a l H e G l y A la C y s T hr S e r Pro T y r A sp G l y L y s T y r T rp S e r M et T y r S e r A rg Leu A rg L y s M et Leu T y r
CTG ATC TAC GTG GCC GGC ATC TCC GTA CGC GTC CAT GTC AGC AAG GAA GAA CAG TAT TAC GAC TAT GAG GAC GCA ACG TTC GAG
L eu H e T y r V a l A l a G l y H e S e r V a l A r g V a l H i s V a l S e r L y s G lu G lu G in T y r T y r A sp T yr G lu Asp A la Thr Phe G lu
Fco R I
BamHl [ S a ll / X h o l)
A CT TAC G C C CTT A CC GGC ATC TCC ATC TGC AAT C CT GGA TCA TCC TTA TGC TGA GACGCT GAATTC GGATCC
GTCGAG
TAA TTT
T h r T y r A l a L eu T h r G l y H e S e r H e C y s A sn Pro G l y S e r S e r L eu C y s S t o p
accaacactactacgttttaactgaaacaaactqqaqactcat

ATG CTG ATC AAC AAC AAG AAG CTG CTT CAT CAC ATT CTG C CC ATC CTG
M et Leu H e A sn A sn L y s L y s L eu Leu H is H is H e Leu Pro H e Leu

GTG C TC G C C CTG CTG GGC ATG CGC ACG GCC CAG GCCTGTT GCG CCA GGC ATC GTC ATC CCG CCG AAG GCA CTG TTC ACC CAA CAG
V a l L eu A l a L e u Leu G l y M et A r g T hr A la G in A l a V a l A l a Pro G l y H e V a l H e P ro Pro L y s A la Leu Phe T hr G in G in
GGC GGC G C C TAT GGA CGC TGC CCG AAC GGA A CC CGC GCC TTG ACC GTG GCC GAA CTG CGC GGC AAC GCC GAA TTG CAG ACG TAT
G l y G l y A l a T y r G l y A r g C y s Pro A sn G l y T h r A r g A l a L eu T hr V a l A la G l u L eu A r g G l y A sn A la G lu Leu G in T hr T y r
TTG C GC CAG ATA ACG C C C GGC TGG TCC ATA TAC GGT CTC TAT GAC GGT ACG TAC CTG GGC CAG GCG TAC GGC GGC ATC ATC AAG
L e u A r g G i n M e t T hr Pro G l y T rp S e r M et T y r G l y Leu T y r A s p G l y T hr T y r Leu G l y G in A la T yr G l y G l y l i e l i e L y s
GAC GCG C CG CCA GGC GCG GGG TTC ATT TAT CGC GAA ACT TTC TGC ATC ACG A CC ATA TAC AAG ACC GGG CAA CCG GCT GCG GAT
A s p A l a P r o P r o G l y A l a G l y Phe H e T y r A r g G l u T hr Phe C y s H e T hr T h r M et T y r L y s Thr G l y G in Pro A la A la A sp
CAC TAC TAC AGC AAG GTC ACG GCC ACG CGC CTG CTC GCC AGC ACC AAC AGC AGG CTG TGC GCG GTA TTC GTC AGG GAC GGG CAA
H i s T y r T y r S e r L y s V a l T hr A l a T hr A r g L eu Leu A l a S e r T hr A sn S e r A r g L eu C y s A l a V a l Phe V a l A rg A sp G l y G in
TCG G T C ATC GGA GCC TGC GCC AGC CCG TAT GAA GGC AGG TAC AGA GAC ATG TAC GAC GCG CTG CGG CGC CTG CTG TAC ATG ATC
S e r V a l H e G l y A l a C y s A l a S e r Pro T y r G l u G l y A r g T y r A r g A sp M et T y r A sp A l a L eu A rg A rg Leu Leu T yr Met l i e
TAT ATG T C C GGC CTT G C C GTA CGC GTC CAC GTC AGC AAG GAA GAG CAG TAT TAC GAC TAC
T y r M e t S e r G l y L eu A l a V a l A rg V a l H i s V a l S e r L y s G l u G lu G in T y r T y r A sp T y r
FcoR I
G C C C TC A CC GGC ATT T CC CTC TGC AAC CCG GCA GCG TCG ATA TGC TGA GCCG CC
GAATTC
A l a L eu T h r G l y H e S e r L eu C y s A sn Pro A l a A l a S e r H e C y s S t o p
CTACGTTTTAACTGAAACAAACTqOAQACTCAT

GAG GAC GCC ACA TTC CAG A CC TAT
G lu A sp A la Thr Phe G in T hr T yr
BamH I ( S a ll/ X h o l)
GGATCC GTCGAG TAA TTTACCAA CACTA

Mie I
ATG AGT ATT CAA CAT TTC CGT GTC GCC CTT ATT C CC TTT IT T GCT AGC TTT TGC CTT
Met S e r H e Gin H i s Phe Arg Val A l a L e u l i e Pro Phe Phe Ala S e r Phe Cys Leu

C C T GTT TTT g c t Tg a c GTT C CT TAT GTG CTG GTG AAG A CC AAT ATG GTG GTC A CC AGC GTA GCC ATG AAG CCG TAT GAA GTC ACC
Pro Val Phe A l a A sp V a l Pro T y r V a l L eu V a l L y s T h r A sn M et V a l V a l T hr S e r V a l A l a M et L y s Pro Tyr G lu V a l Thr
CCG ACG CGC ATG CTG GTC TGC GGC ATC GCC GCC AAA CTG GGC GCC GCG GCC AGC AGC CCG GAC GCG CAC GTG CCG TTC TGC TTC
P r o T h r A r g M e t L eu V a l C y s G l y l i e A l a A l a L y s L eu G l y A l a A l a A l a S e r S e r Pro A sp A la H is V a l Pro Phe C y s Phe
GGC AAG GAT CT C AAG CGT C CC GGC AGC AGT C CC ATG GAA GTC ATG TTG CGC GCC GTC TTC ATG CAA CAA CGG CCG CTG C CC ATS
G l y L y s A s p L eu L y s A r g Pro G l y S e r S e r P ro M et G l u V a l M et L eu A r g A l a V a l Phe M et G in G in A rg Pro Leu A rg M et
TTT CTG GGT C C C AAG CAA CTC ACT TTC GAA GGC AAG CCC GCG CTC GAA CTG ATC CGG ATG GTC GAA TGC AGC
Phe Leu G l y Pro L y s G in L eu T hr Phe G lu G l y L y s Pro A la Leu G lU Leu H e A r g M et V a l G lu C y s S e r
Eco R I
BajnHl ( S a i l / X h o l )
TGC C CC TGA AGGCGA GAATTC
GGATCC
GTCGAG
TAATTTACCAACACTACTACGTTTTAACTGAAACAAACTGGAGACTCAT
C y s Pro S to p

GGC
G Jy
SS
ATG
M et

AAG CAG GAT
L y s G in A sp
CAT A CC ATC
H is T hr I l e

GCA T CC ATC CTG TTG T C C GTG C TC GGC ATA TAC AGC CCG G CT GAC GT c Tg C C GGC TTG CCG A CC CAT CTG TAC AAG AAC TTC ACT
A la S e r I l e
L e u L e u S e r V a l L e u G l y M et T y r S e r Pro A l a A sp V a l A l a G l y L eu Pro T hr H is L eu T yr L y s A sn Phe Thr
GTC CAG GAG
V a l G i n G iu

CTG GCC TTG AAA CTG AAG GGC AAG AAT CAG GAG TTC TGC CTG A CC GCC TTC ATG TCG GGC AGA AGC CTG GTC CGG
L e u A l a L eu L y s L eu L y s G l y L y s A sn G in G iu Phe C y s L eu T h r A l a Phe M et S e r G l y A r g S e r L eu V a l A rg

GCG TGC CTG
A l a C y s L eu

T C C GAC GCG GGA CAC GAG CAC GAC ACG TGG TTC GAC A CC ATG CTT GGC TTT GCC ATA TCC GCG TAT GCG CTC AAG
S e r A s p A l a G l y H i s G iu H i s A sp T hr T rp Phe A sp T h r M et L eu G l y Phe A l a Met S e r A la T y r A la L eu L ys

AGC CGG ATC
S e r A rg I l e

GCG CTG ACG GTG GAA GAC TCG CCG TAT CCG GGC ACT C CC GGC GAT CTG CTC GAA CTG CAG ATC TGC CCG CTC AAC
A l a L eu T h r V a l G iu A s p S e r P ro T y r Pro G l y T hr Pro G l y A sp L eu L eu G iu Leu G in I l e C y s Pro Leu A sn

Feo R I
GGA TAT TGC GAA TGA A CC CT T <GAATTC
G l y T yr C ys G lu S to p

BamHl ( S a l l / ^ h o l )
G TCGAG
<
iG GATCC

TAATTTACCAACACTACTACGTTTTAACTGAAACAAACT ìW AGACTCAT

ATG: CGT
Met A rg

TCG
TGC A CT CGG GCA ATT CGC CAA A CC GCA AGA ACA GGC TGG CTG ACG TGG CTG GCG ATT CTT GCC GTC ACG GCG CCC GTG ACT
C y s T h r A r g A la H e A r g G in T hr A l a A r g T hr G l y Trp Leu T hr T rp Leu A l a l i e Leu A la V a l Thr A la Pro V a l T hr S e r
TTC CAG AAC GGA TTC ACG
CCG GCA TGG GCC L a c GAT C C T C CC GCC A CC GTA TAC CGC TAT GAC TCC CGC CCG CCG GAG GAC GTT
G l y Phe Thr
P ro A l a T rp A l a A sp A sp Pro Pro A la T hr V a l i y r A rg T y r A sp S e r A r g Pro Pro G lu A sp V a l Phe G in A sn
TTC GTC TCC
AAC GAC AAT GTG CTC GAC CAT CTG ACC GGA CGT TCC TGC CAG GTC GGC AGC AGC AAC AGC GCT
GCG TGG GGA
G l y S e r S e r A sn S e r A la Phe V a l S e r
A l a T rp G l y A sn A sn A s p A sn V a l Leu A sp H i s Leu Thr G l y A rg S e r C y s G in V a l
CGC GCC GGC AGG GGC
CGC TAT A CC GAG GTC TAT CTC GAA CAT CGC ATG CAG GAA GCG GTC GAG GCC GAA
A CC AGC AGC
G lu A l a V a l G lu A la G lu A rg A la G l y A r g G l y
T h r S e r S e r S e r A r g A r g T y r T hr G lu V a l T yr Leu G lU H is A rg M et G in
S a il
TAC TTC GAA TAC GTC
GGC TAC ATC TAC GAA GTC CGC GCC GAC AAC AAT TTC TAC GGC GCC GCC AGC TCG
A CC GGC CAC
T
yr
G
lu
Phe
S
e
r
T
yr
S
e
r
A
la
A
la
G
l
y
Phe
T
yr
A sn
T h r G l y H I s Phe l i e G l y T y r l i e T y r G lu V a l A rg A la A sp A sn
CTG GCA CAC CGG CGC ATT
GCC GGC CGT ATC CTC GCC GGC GCG CTG GCC ACC TAC CAG AGC GAA TAT
GAC ACT TAT
A la L eu A la T hr T y r G in S e r G lu T yr Leu A la H is A rg A rg
A sp T h r T y r G l y A sp A sn A l a G l y A rg l i e L eu A l a G l y
CCG C C C GAA
P ro Pro G iu A sn

GAG TAT TCC AAC GCT
AGG GTA ACG CGG GTC TAT CAC AAC GGC ATC A CC GGC GAG ACC ACG ACC ACG

Thr Thr G lu T y r S e r A sn A la
l i e A r g A r g V a l T hr A r g V a l T y r H is A sn G l y l i e T hr G l y G l u T hr T hr

TTG GTG
A CT CGC GCC AAT C CC AAC CCC TAC ACA TCG CGA AGG TCC GTA GCG TCG ATC GTC GGC ACA
CGC TAC GTC
Pro T y r T hr S e r A r g A r g S e r V a l A la S e r H e V a l G l y T hr Leu
A r g T y r V a l S e r G in G in T h r A r g A l a A sn Pro A sn
TCC GAA CGC GCC GGC GAG
GCT TGC ATG GCG CGG CAG GCC GAA AGC TCC GAG G CC ATG GCA GCC TGG
CAT GGC GCC
M et A l a A r g G in A la G l u S e r S e r G l u A l a M e t A l a A l a T rp S e r G lu A rg A la G l y G lu
H i s G l y A l a G l y A sp S e r A l a C y s
E co RI
BamHl
Sal I
GAA AGC ATC GCG TAT TCG TTC TAG ACCTGG GAATTC GGATCC GTCGAC
GCG ATG GTT CTC GTG TAC TAC
G l u S e r l i e A l a T y r S e r Phe S t o p
A l a M et V a l L eu V a l T y r T y r

Figure 17. The 3308 base pair nucleic acid sequence of the recombinant PT operon encoded by
pDP16 which directs expression of the five PT subunits in E. coli. The atpE translation initiation
region is underlined, whilst the Shine-Dalgamo sequences are given in bold print. The leader peptide
processing points for each subunit are given by arrows and the modified 8-lactamase leader peptide
fused to the S4 subunit is italicised. Relevant restriction enzyme sites are given above the nucleotide
sequence whilst sites where Sail and Xhol restriction sites have ligated together are indicated in
brackets above the nucleotide sequence (Sall/Xhol).

3 .1 .7 Growth Rate of E. coli KS476 (pDP16) following Temperature
Induction

The growth rate o f E.coli KS476 harbouring the recom binant PT operon was
assessed following temperature induction at 42°C. It was found that E. coli KS476
(pDP16) show ed a reduction in growth compared to vector only or plasmid-less
strains following temperature induction at 42°C (Figure 18).

Time (min)

Figure 18. Growth rate o f E. coli KS476 (pDP16) following temperature induction at 42°C
compared to vector-only or plasmid-less strains. The time of induction is indicated by an arrow.

3 . 1 . 8 C e llu la r L o catio n o f E x p ressed P e rtu ssis T oxin S u b u n its in
E . coli K S 476

(pD P 16)

Since all five PT subunits were shown to be at least partially processed in E. coli
KS476, the possibility that periplasmic extracts may contain pertussis holotoxin was
investigated by sub-cellular localisation experiments. Fractionation studies (2.5.8)
using KS476 (pDP16) revealed that processed SI and S3 subunits (Figure 19) were
found in the soluble periplasmic fraction after osmotic shock whereas S2 (Figure
19B), S4 and S5 were not detected (results not shown), suggesting that the
processed form of these subunits may be membrane associated or in an insoluble
form. The majority of all PT subunit proteins detected in this assay were found to be
cytoplasmic.
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Fieure 19 Western blot analysis o f KS476 (pDP16) fractionation experiments. In all panels lane 1
contains w hole ce ll extract; lane 2, cytoplasm ic fraction; lanes 3. periplasmic fraction; lane 4,
extracellular fraction; lane 5, purified PT. Panel B, lane 4 was taken ftom another western blot. PT
subunits were detected using specific antiserum: panel A, an ti-S l, panel B anU-S2 and S3.
e
filled arrowheads indicate processed PT subunits whilst the open arrowheads indicate PT subunit pre
proteins.
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3 .1 .9 D iscussion

The ability to express recombinant pertussis holotoxin in E. coli would provide a
safe alternative to acellular whooping cough vaccine manufacture. In this research,
the five PT genes have been individually expressed in E. coli C A G 629 and
subsequently, a recombinant operon capable of simultaneously expressing the five
PT genes has been constructed. The recombinant PT plasmids examined in this work
were found to produce greater amounts of PT subunit protein compared to B .
pertussis Tohama I. In contrast to a previous study (Burnette et aL, 1988a), we have
achieved individual PT subunit expression using native leader sequences, and in the
case of S4 using a modified leader sequence, with at least partial leader peptide
processing of each subunit in E. coli CAG629.

For studies of simultaneous expression of PT subunits in E. coli, the results obtained
indicated that expression of each subunit was dependent upon the position of each
subunit gene in the synthetic operon. The positioning o f the PT subunits in the
follow ing order, S2+S3+S4+S5+S1 (pDP16) and S3+S2+S4+S5+S1 (pDP20)
resulted in expression of all five subunits. Signal peptide processing of the PT genes
was found to be dependent on the host cell strain used; E. coli KS476 seemed to
process the greatest amount of PT subunit protein especially for S4 and S5,
com pared to all other E. coli strains investigated. Fractionation experiments to
determ ine the cellular location of PT subunits indicated that in E. coli KS476
(pDP16), SI and S3 were exported to the periplasm. Processed forms of S2, S4 and
S5 were not detected in soluble periplasmic extracts, indicating that these subunits
may be in an insoluble form or membrane associated. Surprisingly, processed forms
o f SI and S3 were also detected in the extracellular fraction. The absence of SI and
S3 pre-proteins in these fractions precludes the possibility that the supernatant
contains the cellular contents of bacterial cells lysed during induction. Possibly,
expression of the five PT subunits has resulted in a weakening of the E. coli outer

membrane, resulting in the release of the soluble periplasmic contents. The growth
rate of E. coli KS476 (pDP16) following induction at 42°C was found to be reduced
compared to vector only or plasmid-less strains (results not shown), indicating the
expression of PT subunits in E. coli KS476 had an adverse effect on cellular
physiology.

3 .2

Expression of Pertussis Toxin Subunits in S. typhim urium
aroA spp.

The expression of PT subunits in S. typhimurium aroA would provide a means by
which to deliver an oral pertussis vaccine; other B. pertussis antigens such as FHA
(Guzman et aL, 1991a; Parker et al., 1990) and P69 (Strugnell et al., 1992) have
previously been expressed in Salmonella spp. B. pertussis is a respiratory pathogen,
thus vaccines capable of inducing local mucosal immune responses at the site of
colonisation are desirable. Previous research has shown that it is possible to express
the SI subunit of PT in Salmonella spp. either as a native protein (Walker et al.,
1992) or as a fusion to the tetanus toxin fragment C (Barry et al., 1996).
Additionally, it was possible to stimulate a lung mucosal immune response in mice
following oral (Walker et al., 1992) or intranasal (Barry et al., 1996) immunisation
of mice with S. typhimurium aroA SL3261 and S. typhi CVD908 respectively. The
PT subunits S2 to S5, have not previously been expressed in Salmonella spp. In this
research, all five PT subunits were expressed in a vaccine strain of S. typhimurium
aroA for oral immunisation against pertussis. The five PT subunits in the form of
holotoxoid are thought to be required for the correct presentation of protective
epitopes (Bartolini et al., 1988; Burnette et al., 1992b). S. typhimurium aroA strains
were initially chosen as vaccine vectors in this work because aroA mutants of
Salmonella spp. have been extensively characterised and are considered safe for
human use (Tacket et al., 1992). S. typhimurium aroA SL3261 specifically, was
chosen for expression and immunisation studies since it had previously been used
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successfully to engender an immune response against the SI subunit in mice (Walker
et al., 1992).

3 . 2 . 1 E x p ressio n of th e In d iv id u a l P e rtu ssis T oxin S u b u n it G enes in
S. ty p h im u riu m a ro A

To facilitate transformation into Salmonella vaccine strains, extracted plasmid DNA
was first transformed into S. typhimurium aroA SL5283 R 'M +(Table 5). Plasmid
DNA was subsequently extracted and transform ed into S. typhimurium aroA
SL3261. After induction of mid log-phase cultures (2.7.2) at 42°C for 1 h, whole
cell extracts were subjected to SDS-PAGE (2.7.2) and then Coomassie blue staining
(2.7.3) or W estern blot analysis (2.7.5). W estern blot analysis revealed that the
recombinant S5 subunit was completely processed, whilst all other PT subunits were
partially processed in S. typhimurium aroA SL3261 (Figure 20). All recombinant PT
subunits were detected at levels significantly higher than those found in B. pertussis
Tohama I (results not shown).
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Figure 20. W estern blot analysis o f individual PT subunit expression in S. typhimurium aroA
SL 3261. In all panels lane 1 contains SL3261 (pJLA506), except in panel C which contains
SL3261 (pC G V l), whilst lane 2 contains the recombinant single PT subunit expression plasmid in
SL3261: panel A, SI; panel B, S2; panel C, S4; panel D, S5. Panel B lane 2’ contains SL3261
bearing the S3 subunit expression plasmid. Lane 3 contains purified PT. PT subunits were detected
using specific antiserum; panel A, anti-Sl; panel B, anti-S2 and S3; panel C, anti-S4; and panel D,
anti-S5. The filled arrowheads indicate the processed PT subunits whilst the open arrowheads
indicate PT subunit pre-proteins.
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3 .2 .2 Growth Rate of S. typ h im u riu m aroA SL3261 Expressing
Individual Pertussis Toxin Subunits

To determine whether PT subunit expression affected survival of S. typhimurium
aroA SL3261, the growth rate of this strain following temperature induction at 42°C
was investigated. All recombinant PT subunit expressing strains displayed some
reduction in growth rate compared to vector only or plasmid-less strains (Figure
21A-F). The growth rate of S. typhimurium aroA SL3261 expressing the SI subunit
was least affected by temperature induction (Figure 21 A), whilst the S5 expressing
strain showed the greatest decrease in growth rate following temperature induction at
42°C (Figure 21F).

3 .2 .3 Simultaneous Expression of Pertussis Toxin Subunit Genes in
S. typ h im u riu m aroA spp.

Follow ing the expression of individual PT subunits in S. typhimurium aroA
SL3261, the same strategy was used for simultaneous expression of subunits in this
strains as for E. coli. A number of different combinations of PT subunit genes were
assessed for subunit production in S. typhimurium aroA SL3261 (Figure 22). The
S2+S1 construct (pDP13) produced both subunits simultaneously but when S5 was
added, expression of all three subunits was abolished (pDP15). However, when the
S4 subunit was added to S5+S2+S1 (pDP17) expression of all subunits except S5
was detected. A similar observation was made for the S5+S1 construct (p D P ll)
(Figure 22).
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SL3261
SL3261 (pJLA506)
Muoggv

SL3261 (pJLA506 SI)
SL3261 (PJLA506 S2)
SL3261 (pJLA506 S3)
SL3261 (pCGVl S4)
SL3261 (pJLA506 S5)

Time (min)

Time (min)

Figure 21. Growth curves o f S. typhimunum aroA SL3261 expressing the individual PT^subunits.
Panel A, SL3261 and SL3261 (pJLA506); panel B, SL3261 (pJLA5(tf) and S L 3 2 6 _ 1 ^ A 5 0 6 S 1);
panel C, SL3261 (pJLA506) and SL3261 (pJLA506 S2); panel D, SL3261 (PJLA50Q and SL3261
(pJLA506 S3); panel E, SL3261 (pJLA506) and SL3261 (pCGVl S4); panel F, SL3261 (pJLA506)
and SL3261 (pJLA506 S5). Arrows indicate the time of induction.
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Figure 22. Western blot analysis o f S I subunit expression in S. typhimurium aroA SL3261. Lane
1 contains SL3261 (pJLA506); lane 2, SL3261 (pJLA506 SI); lane 3, SL3261 (p D P ll); lane 4,
SL3261 (pDP13); lane 5, SL3261 (pDP15); lane 6, SL3261 (pDP17); lane 7 contains purified PT.
The SI subunit was detected using anti-Sl antiserum. The filled arrowhead indicated processed SI
protein whilst the open arrowhead indicates SI pre-protein.

The addition of S2 to p D P ll abolished expression of S5 (pDP18). When S4 was
added to S5+S1, expression of all subunits was maintained (pDP12). The addition
of S2+S3 (pDP14) to this construct resulted in expression of the five PT subunits
(S2+S3+S4+S5+S1) (pDP16). Similarly, the addition of S3+S2 (pDP19) to pDP12
resulted in expression of the five subunit genes (pDP20) (Figure 23).

Expression of all subunits in the multiple PT expression constructs (pDP16) and
(pDP20) was detected either at similar or lower levels to that of the individual
recom binant PT subunits (results not shown). W estern blot analysis of S.
typhimurium aroA SL3261 (pDP20) indicated that the S2 subunit was poorly
expressed from pDP20, additionally the growth rate of SL3261 containing pDP20
was lower than that of SL3261 containing pDP16 (results not shown). Future
expression studies therefore only utilised pDP16. The pDP16 construct was
subsequently transformed in S. typhimurium aroA SL7207 (Table 5).
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Figure 23. Simultaneous expression o f multiple PT subunits in S. typhimurium aroA SL3261. PT
subunit gene constructs are shown with their corresponding ability to express subunit proteins in S.
typhimurium aroA. Recombinant PT subunit genes are given as open arrows; expression is indicated
by a plus sym bol (+) whilst no detectable expression is indicated by a minus symbol (-). The S4
subunit has had the wild-type leader sequence replaced with a modified 6-lactamase leader sequence
(open box).
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This S. typhimurium aroA strain was used because it was considered less attenuated
than SL3261 (C. Guzman, personal communication), therefore this strain should be
theoretically better at engendering an immune response in subsequent immunisation
studies. Analysis of the size of immunoreactive bands detected in W estern blots
indicated that in S. typhimurium aroA SL3261 (results not shown) and SL7207
(Figure 24) containing the synthetic PT operon, S5 was completely processed and
S I was partially processed, whilst S2, S3 and S4 remained unprocessed.

Figure 24. Simultaneous expression o f PT subunits in S. typhimurium aroA SL7207. In all panels
lane 1 contains SL7207 (pJLA506), except in panel C which contains SL7207 (pC G V l), whilst
lane 2 contains SL7207 bearing pDP16. Lane 3 contains purified PT. PT subunits were detected
using specific antiserum: panel A, anti-Sl; panel B, anti-S2 and S3; panel C, anti-S4; and panel D,
anti-S5. The filled arrowheads indicate processed PT subunits whilst the open arrowheads indicate
PT subunit pre-proteins.

3 . 2 . 4 G ro w th R ate of S. typhim urium aroA SL7207 (pDP16)
follow ing T e m p e ra tu re In d u ctio n

The growth rate of S. typhimurium aroA SL3261 (pDP16) and SL7207 (pDP16)
follow ing tem perature induction was determined. As was the case with the
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individually expressed subunits, S. typhimurium aroA SL3261 (result not shown)
and S. typhim urium aroA SL7207 (Figure 25) expressing the recom binant PT
operon showed a decrease in growth rate following temperature induction at 39.5°C
or 42°C. The growth rate o f S. typhimurium aroA SL3261 and S. typhimurium aroA
SL7207 either alone or harbouring the expression plasm id pJLA506 were not
adversely affected by temperature induction. W estern blot analysis of the induced
cultures indicated that at 37°C only the S 1 subunit was detected, whilst at 39.5°C and
at 42°C all subunits were expressed (results not shown). Thus 39.5°C was chosen as
the induction temperature for S. typhimurium aroA SL3261 and 5. typhimurium
aroA SL7207 since expression of all subunits was maintained and growth rate was
higher at 39.5°C compared to 42°C.

□

30°C

O

37°C

O

39.5°C

A

42°C

Time (min)

Figure 25. Growth curve of S. typhimurium aroA SL7207 (pDP16) following temperature
induction. Strains were grown at 30°C then subsequently temperature induced at 37°C, 39.5°C or
42°C. The time o f induction is indicated by an arrow.
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3.2.5

I n te r a c tio n s o f V a c c in e S tr a in s w ith E u k a r y o te C ells

To determ ine w hether the expression o f PT subunits in S. typhimurium aroA
SL3261 or SL7207 had any affect on the ability of these strains to invade eukaryote
cells, an in vitro eukaryote cell invasion assay (2.8.1) was undertaken by D r C.
Guzman. The results presented in Table 9 show that vector only and plasmid-less
strains o f S. typhimurium aroA SL3261 and S. typhimurium aroA SL7207 increased
1.6 to 10.7 fold in the number o f CFU recovered between 4 h and 24 h. Similarly,

S. typhimurium aroA SL3261 (pDP16) and S. typhimurium aroA SL7207 (pDP16)
induced at 37°C increased 8.3 and 8.6 fold respectively. However, S. typhimurium

aroA SL3261 and S. typhimurium aroA SL7207 containing pDP16 induced for 1 h
at 39.5°C decreased 11.5 and 10 fold respectively in invasive ability (Table 9).
Table 9. In vitro invasiveness o f vaccine strains and control strains after 1 h induction at 37°C and 39.5°C.

Strain

SL3261
SL3261 (pJLA506)
SL3261 (pDP16)
SL7207
SL7207 (pJLA506)
SL7207 (pDP16)

Invasivenessa
4h
37°Cb

24 h
37°Cb

1.8
2.2
2.4
1.9
1.4
2.2

1.4
1.6
2.0
1.9
1.5
1.9

x
x
x
x
x
x

105 ± 14800
105 ± 99200
105 ± 57500
105 ± 52300
105 ± 22300
105 ± 28500

x
x
x
x
x
x

4h
39.5°CC

106 ±
106 ±
106 ±
106 ±
106 ±
106 ±

240000
365000
526000
201000
303000
178000

1.8
2.0
7.1
3.9
2.4
2.0

x
x
x
x
x
x

105 ± 14800
105 ± 37600
104 19500
105 ± 9000
105 ± 24600
10*4 ± 3000

aCFU of viable intracellular bacteria per well ± standard deviation.
bstrains were grown overnight at 37°C.
cstrains were grown overnight at 30°C, then incubated at 37°C for 2 h and then 39.5°C for a further 1 h.

24 h
39.5°CC

5.2 x
4.3 x
6.2 x
1.2 x
4.0 x
2.0 x

105 ±
105 ±
103 ±
106 ±
105 ±
103 ±

14200
11000
1060
40000
44000
4040
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3 .2 .6 Antibody responses specific for PT in vaccinated mice

The immunogenicity of S. typhimurium aroA SL7207 (pDP16) was determined by
oral immunisation of mice with a bacterial suspension of vaccine preparation, using a
vaccination schedule previously shown capable of generating antibody responses
(Walker et aL, 1992). Mice were examined for the presence of antibodies specific for
PT in sera and lung washes following oral immunisation (2.9) with S. typhimurium
aroA SL7207 (pDP16) or SL3261 (pDP16) induced at 37°C or 39.5°C for 1 h.
Antibody responses against PT were not detected when SL3261 was used as the
carrier strain (results not shown). A statisically significant (P<0.05) serum anti-PT
IgG response was detected in mice immunised with S. typhimurium aroA SL7207
(pDP16) induced at 39.5°C (Table 10) but not at 37°C (results not shown). Some
mice immunised with SL7207 (pDP16) induced at 39.5°C also showed low levels of
IgA in the sera (Table 10), however these responses were not statistically significant.
Anti-PT antibodies were not detected in the lung lavages of any vaccinated mice
(results not shown). Intraperitoneal immunisation with pertussis toxoid (Munoz et
aL, 1980) generated high serum antibody responses. Western blot analysis was then
performed to determine the PT subunit specificity of the antibody response. The sera
from mice orally immunised with S. typhimurium aroA SL7207 (pDP16) induced at
39.5°C for 1 h showed a detectable response only against the SI subunit protein of
PT in five of ten mice (Table 10; Figure 26). Sera from mice immunised with
pertussis toxoid showed a strong response against the SI subunit protein (Table 10;
Figure 26), whilst only one mouse from this group responded strongly against SI
and weakly against S4 and S5 (results not shown). Sera from mice orally immunised
with S. typhimurium aroA SL7207 (pJLA506) induced at 39.5°C for 1 h or with
PBS did not react against any of the five PT subunits (Figure 26).
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Table 10. Summary o f anti-PT titres. S. typhimurium SL7207 containing pJLA506 or pDP16 were
induced for 1 h at 39.5°C prior to oral immunisation.

Serum IgG

Serum IgA

Reactivity in Western
Blotb

1
2

256
256

32
256

++
++

3
4
5
6
7
8
9
10

64
<16
<16
128
64
128
512
128

32
32
32
<16
<16
<16
<16
<16

+

1
2
3
4
5

182272
182272
91136
45568
91136

500
256
16
256
32

+++++
++++
+++
++++
+++

1
2
3
4
5

<16
<16
<16
<16
<16

<16
<16
<16
<16
<16

1
2
3
4
5
6
7
8
9
10

<16
<16
<16
<16
<16
<16
<16
<16
<16
<16

<16
<16
<16
<16
<16
<16
<16
<16
<16
<16

Vaccination groupa

SL7207pDP16

PT

PBS

-

+
-

+
-

-

-

-

aR esults for individual m ice are presented.

bNo detectable reactivity after western blot was scored as a *-* symbol, whilst detectable reactivity was
scored in a range from *+* to ‘+++++’.
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Figure 26. W estern blot analysis o f representative mouse sera specific for PT. Lane 1: S.
typhimurium aroA SL7207 (pDP16) immunised mouse; lane 2: PT immunised mouse; lane 3:
SL7207 immunised mouse; lane 4: PBS immunised mouse. The filled arrowhead indicates the SI
subunit protein.

3 .2 . 7 P ro te ctiv e n e ss of 5. typhim urium aroA SL7207 (pD P16)
V accine S tra in in M ice

The ability of S. typhimurium aroA SL7207 (pDP16) to engender an antibody
response against PT following oral immunisation of mice, necessitated that the
protectiveness of this vaccine strain be investigated. Mice were orally vaccinated with
this vaccine strain once at day 0 and then intracerebrally challenged with B. pertussis
18-323 on day 14 (2.9.3). The number of surviving mice 14 days following
challenge is shown in Table 11. These results indicated that S. typhimurium aroA
SL 7207
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mice following intracerebral challenge. The Australian standard C dose consists of
killed B. pertussis cells formulated to give 50% survival of vaccinated mice in this
assay.
Table 11. Number of surviving mice following intracerebral challenge.

Vaccination group

Number of mice/group

Number of survivors

SL7207(pDP16)

21

2

Aust. Std. C dose

16

8

SL7207(pJL A506)

12

0

PBS

16

2

3 .2 .8 D iscussion

W hooping cough is a serious respiratory disease of infants. Both the conventional
whole cell and acellular anti-pertussis vaccines employ an intramuscular route of
immunisation, mainly stimulating a systemic immune response. It may be considered
more effective to develop anti-pertussis vaccines capable of stimulating an IgA
response in the respiratory tract, the site of colonisation. The production of a local
secretory antibody response may hinder bacterial attachment and subsequent
colonisation of the respiratory tract, thus preventing disease. In addition to
stimulating a lung mucosal immune response, the development of enteric delivery
systems for pertussis antigens would also eliminate the need for purification of
individual vaccine components thereby reducing production costs.

This research has shown that it is possible to express all five individual PT subunits
in S. typhimurium aroA SL3261. A recombinant PT operon has been constructed
and transferred into S. typhim urium aroA SL3261 and SL7207, where the
simultaneous expression of the five PT subunits was detected. The SI subunit of

PT has previously been expressed in S. typhimurium aroA SL3261 (Walker et al.,
1992). Another group has recently expressed SI as a fusion protein using the amino
or carboxyl terminus fused to the tetanus toxin fragment C in S. typhi aroA (Barry et
al., 1996). All other PT subunits apart from SI have not previously been expressed
in attenuated Salmonella spp.

In order to express the five PT genes in S. typhimurium aroA, a series of PT subunit
expression plasmids were engineered. Results obtained indicated that the expression
of each PT subunit was dependent upon the position of each subunit gene within the
operon. In most instances, those constructs which expressed PT subunits in E. coli
strains were also expressed in S. typhimurium aroA. The positioning of the subunit
genes in the following order S2+S3+S4+S5+S1 (pDP16) resulted in production of
all five PT subunits. Although another PT construct was also made containing the
five PT subunits, expression of the S2 subunit in this construct was reduced
compared to its expression in pDP16. Generally, signal peptide processing was
found to be the same in both the S. typhimurium aroA strains investigated. In strains
containing plasmids directing the expression of individual PT subunits, S5 was
completely processed, whilst S I, S2, S3 and S4 were partially processed. In strains
containing pDP16, S5 was completely processed, SI was partially processed whilst
processed forms of S2, S3 and S4 were not detected.

The growth rate of S. typhimurium aroA strains containing pDP16 was also
investigated. Results obtained indicated that the growth rate of both strains
containing pDP16 was progressively reduced following induction at 37°C, 39.5°C or
42°C compared to vector only or plasmid-less strains. This reduced growth rate
indicated PT subunit expression was detrimental to cellular physiology. In order to
achieve a balance between bacterial cell growth rate and PT subunit production, the
use of different induction temperatures for the expression of individual PT subunits
from pDP16 was investigated. These experiments showed that at 37°C, only SI

92
expression was detectable, whilst at 39.5°C and 42°C expression of all five subunits
was apparent. Thus 39.5°C was chosen as the optimum temperature for achieving a
balance between strain growth rate and subunit expression. Results obtained in the
eukaryote cell invasion assays correlated to that of bacterial growth rate. The
invasiveness of strains containing pDP16 was significantly lower than vector only
and plasmid-less controls at 39.5°C, whilst no significant differences were detected
at 37°C.

Mice orally immunised with S. typhimurium aroA SL7207 (pDP16) showed a serum
antibody response directed against the immunodominant SI subunit, whereas S.
typhim urium aroA SL3261 (pDP16) failed to stimulate a detectable antibody
response. Lack of reactivity to the B-oligomer may not necessarily mean antibodies
are absent in sera; such antibodies may react only with conformational epitopes.
Differences in the immune response of these two strains may reflect differences in
the attenuation of S. typhimurium aroA SL3261 and S. typhimurium aroA SL7207.
The protective ability of S. typhimurium aroA SL7207 (pDP16) was assessed in a
mouse intracerebral challenge assay. This strain was found not to protect mice from
challenge with B . pertussis 18-323.
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4.

DISCUSSION

The expression of recombinant pertussis holotoxin in E. coli would provide a means
of which to produce large amounts of a pertussis vaccine antigen in a background
devoid of other potential factors that may be responsible for deleterious side effects
of vaccine preparations currently in use. Additionally, using E. coli fermentation
conditions would provide a cost effective means of production, in contrast to B.
pertussis fermentation requirements. In this research, the five PT genes have been
individually expressed in E. coli and a recombinant operon capable of simultaneously
expressing the five PT genes has been constructed. Expression of the PT subunits
was found to be variable and dependent on both the E. coli host strain used and more
im portantly the order of the PT genes with respect to one another within the
recombinant operon. The recombinant PT plasmids constructed in this study were
found to produce greater amounts of PT subunit protein compared to B. pertussis
Tohama I.

In this study, the individual PT genes have been expressed with at least partial leader
peptide processing of each subunit in E. coli. This is in contrast to a similar study
where use of the native leader sequences resulted in complete processing of only the
SI subunit, partial processing of S2 and S5 was observed, whilst S3 remained
unprocessed and S4 was not expressed (Burnette et al., 1988a). Differences in the
levels of processing described may be the result of differences in the bacterial strain
used in the two studies. The previous study utilised E. coli FM5, a derivative of E.
coli K-12 whilst in this study E. coli CAG629, EC538, H179, YA21, 876 were
used. Individual PT subunit expression may be enhanced by further investigating the
use of other protease deficient E. coli strains.

Results of this research indicated that expression of each subunit was dependent
upon the position of each subunit gene in the synthetic operon. The positioning of
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The expression of recombinant pertussis holotoxin in E. coli would provide a means
of which to produce large amounts of a pertussis vaccine antigen in a background
devoid of other potential factors that may be responsible for deleterious side effects
of vaccine preparations currently in use. Additionally, using E. coli fermentation
conditions would provide a cost effective means of production, in contrast to B.
pertussis fermentation requirements. In this research, the five PT genes have been
individually expressed in E. coli and a recombinant operon capable of simultaneously
expressing the five PT genes has been constructed. Expression of the PT subunits
was found to be variable and dependent on both the E. coli host strain used and more
im portantly the order of the PT genes with respect to one another within the
recombinant operon. The recombinant PT plasmids constructed in this study were
found to produce greater amounts of PT subunit protein compared to B . pertussis
Tohama I.

In this study, the individual PT genes have been expressed with at least partial leader
peptide processing of each subunit in E. coli. The results of periplasmic fractionation
experiments indicated that the S3 subunit was also processed in pDP16, supporting
the results obtained by western blotting experiments. This is in contrast to a similar
study where use of the native leader sequences resulted in complete processing of
only the S I subunit, partial processing of S2 and S5 was observed, whilst S3
rem ained unprocessed and S4 was not expressed (Burnette et al., 1988a).
Differences in the levels of processing described may be the result of differences in
the bacterial strain used in the two studies. The previous study utilised E. coli FM5,
a derivative of E. coli K-12 whilst in this study E. coli CAG629, EC538, H179,
YA21, 876 were used. Individual PT subunit expression may be enhanced by further
investigating the use of other protease deficient E. coli strains.

R esults o f this research indicated that expression o f each subunit was dependent
upon the position o f each subunit gene in the synthetic operon. The positioning o f
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the PT subunits in the follow ing order, S2+S3+S4+S5+S1 (pDP16) and
S3+S2+S4+S5+S1 (pDP20) resulted in expression of all five subunits. Signal
peptide processing o f the PT subunits was found to be dependent on the host cell
strain used; the E. coli strain KS476 seemed to process the greatest amount of PT
subunit protein especially for S4 and S5. Differential construct expression may have
been the result of differences in mRNA stability or the formation of RNA secondary
structure. In a study investigating the transcription and translation of the genes
encoding the subunits o f the E. coli H + ATPase it was suggested that mRNA
secondary structure may limit the rate of translation initiation (McCarthy and
Bokelmann, 1988). It was shown that constructs with less extensive and stable
secondary structures exhibited higher rates of translation, and the translational
efficiencies o f the genes were influenced by the length and sequence of the
translation initiation region. This study also found that the expression level of one
subunit was dependent on the presence of the upstream subunit gene.

A num ber o f methods can be investigated in order to achieve greater levels of
processing o f those PT subunits which were only partially processed. Export of
proteins depends on the properties of both the exported protein and the export
machinery o f the host bacterium. Firstly, examining the exported protein, the NH2
leader peptide can be replaced with an E. coli leader sequence such as the modified 8lactamase leader sequence used in this study that directs secretion of recombinant
gene products. Use of this leader sequence in this study, resulted in complete
processing of the S4 subunit in E. coli KS476 (pCGVl S4). Alternatively, the E.
coli signal peptidase 1 could be over-expressed in the same bacterial system so as to
increase the yield o f processed PT subunits. The availability of E. coli signal
peptidase 1 is a limiting factor in protein export in E. coli, particularly with respect to
precursor proteins showing low signal peptide processing abilities. The over
production of the E. coli signal peptidase 1 has been shown to result in increased
rates o f pre(A13i)-6-lactamase processing (Van Diji et aL, 1991). Additionally, E.

coli signal peptidase 1 has previously also been successfully over-expressed in E.
coli M V1190 (Kim et al., 1995). Thus, this research indicates that it may be
possible to use such an expression system in combination with that developed in this
study, to achieve increased processing of PT subunit genes.

The bacterial export machinery of E. coli is presently the most well characterised
secretion system, and optimisation of this pathway represents another method which
may result in increased processing of those PT subunits that were only partially
processed. In this Gram-negative bacterium, proteins destined for secretion must
transverse the inner membrane into the periplasmic space. The majority of proteins
secreted to the periplasm use the sec-dependent general secretory pathway (Pugsley,
1993). It is well established that although signal peptides may lack primary sequence
homology, shared properties enable different signal peptides to interact with common
elements in the general secretory pathway. To enable proper processing, proteins
utilising this pathway must remain in a transport competent conformation before and
during translocation, and the requirements on the signal sequence, determined by the
host's transport system must be met. Chaperone proteins perform the function of
maintaining the protein precursors in an export competent conformation by either
stabilising an unfolded conformation or by preventing their aggregation (Pugsley,
1993). It is known that some of these membrane proteins combine to form a
translocase complex, whilst, the function of other export machinery components has
yet to be determined. In E. coli, numerous different chaperones have been shown to
interact with different proteins. The substrate specificity of the chaperone-protein
interaction may require cloning and co-expression of a chaperone from the same
heterologous organism for successful expression and processing of a heterologous
extracellular protein in E. coli (Waldinger et al., 1988). When certain chaperones are
missing or deficient in high-level expression systems, the transport through the inner
membrane may become inefficient (Kane and Hartley, 1988). Several attempts have
been
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components of the general secretory pathway. Results of this research indicate that
whilst it is lethal to overproduce the transmembrane SecY (PrlA) protein in E. coli
(Ito, 1990), over-expression of SecY and SecE simultaneously in E. coli maintained
cell viability (Matsuyama et al., 1990). Increasing the SecB content of E. coli has
previously been used to facilitate the export of a recombinant penicillin-binding
protein in E. coli (Fraipont et al., 1994). In another study, it was found that the co
expression of PrlA4, a mutant form of the SecY protein, and SecE resulted in
increased yields of recombinant pre-(OmpA)-hIl-6 fusion protein in the periplasm of
E. coli DH1 (Perez-Perez et al., 1994). Recent work has demonstrated that the over
expression of prlF increases cell viability and enzyme yields in recombinant E. coli
expressing Bacillus stearothermophilius alpha-amylase (Minas and Bailey, 1995).
The over-expression of the chaperone protein PrlF helps to overcome the lethal
jam m ing of the transport system by B-galactosidase fusion proteins, increasing the
efficiency with which secY translocates the fusion protein (Kiino et al., 1990; Kiino
and Silhavy, 1984). Additionally, PrlF directly activates the Lon protease, involved
in the degradation of precursors of exported proteins accumulated in the cytoplasm
(Gottesman, 1989; Snyder and Silhavy, 1992). Other research has found that over
production of SecB or DnaK plus DnaJ resulted in a marked increase of hGM-CSF
secretion to the periplasm. This increase was found to be dependent on the signal
peptide-heterologous protein-chaperone association involved, thus indicating the
substrate specificity of chaperone proteins (Berges et al., 1996). The question of
whether E. coli leader peptidases or chaperone proteins will be functional for all B.
pertussis PT subunits has yet to be examined, however, such strategies may be
investigated to improve the level of processing of those PT subunits that were
unprocessed or partially processed.
The use o f B. pertussis chaperones and/or leader peptides may be required if
processing o f the PT subunits is not improved by E. coli signals or chaperones.
H ow ever, the B. pertussis signal peptidase 1 gene has yet to be cloned or

characterised. A chaperone from B. pertussis, has however been identified and
immunogenically characterised. This chaperone termed cpn 60, has been shown to
be very similar to the GroEL chaperone of E. coli (Bums et al., 1991). However,
studies determining its effects on processing of B. pertussis proteins have yet to be
undertaken.

PT assembly occurs following secretion of individual PT subunits to the periplasm
(Johnson and Bum s, 1994; W alker et al., 1991b). This is also the case for another
typical A/B bacterial toxin, cholera toxin (Hirst and Holmgren, 1987). The excretion
o f pertussis holotoxin into the culture supernatant by B. pertussis is thought to
involve nine accessory genes designated pertussis toxin liberation (ptl) genes (Farizo
et al., 1996; W eiss et al., 1993). These genes are under the control of the PT
promoter (Kotob et al., 1995; Ricco et al., 1996) which also directs the expression
of the PT subunit genes. The cloning and expression of these accessory genes using
strategies developed in this study may result in the export and excretion of
recombinant PT holotoxin into the extracellular medium following assembly in the
periplasm. Several lines of evidence suggest that once PT subunits are secreted into
the bacterial periplasm, pertussis holotoxin will form without the aid of ptl gene
products, chaperone proteins or other factors produced by B. pertussis. Firstly, the
B-oligomer o f PT has been reformed in vitro using recombinant subunits purified
from E. coli, albeit with a relatively low yield (Burnette et al., 1992a). Secondly, an
avirulent strain of B. bronchiseptica {bvg-negative) which contains a constitutively
expressed PT operon has been constructed. Although PT was not excreted from this
strain (which does not express p tl nor other b v g - activated gene products),
periplasm ic extracts were found to contain pertussis holotoxin (W alker et al.,
1991b). Thus it seems likely that, once the five PT subunits are secreted into the
periplasm o f attenuated Salmonella spp., pertussis holotoxin will be formed. The
possible requirem ent for increased amounts of the S4 gene product could be
addressed by cloning an additional copy of this gene into the expression vector

construct. Procedures for the genetic detoxification of PT could then be employed
(N encioni et a l., 1990) in order to engineer attenuated vaccine strains for PT
holotoxoid expression.

In addition to providing a means of producing a highly purified non-reactogenic
acellular vaccine component, the cloning strategy developed in this study should also
find utility in the construction of recom binant operons for the regulation and
expression o f other heterologous genes which are not normally transcribed and
translated in E. coli. Such genes might include those involved in nitrogen fixation
and the gene products o f pathways involved in the degradation of aromatic
compounds.

Current vaccines against whooping cough are administered parenterally, and generate
a systemic immune response. An alternative to this approach is to stimulate mucosal
and systemic immune responses by oral immunisation with live vaccine strains of
Salmonella spp. The production of a local secretory antibody response may hinder
bacterial attachm ent and subsequent colonisation of the respiratory tract, thus
preventing colonisation and disease. In addition to stimulating a lung mucosal
immune response, the development of enteric delivery systems for pertussis antigens
would also eliminate the need for purification of individual vaccine components from
B. pertussis thereby reducing production costs.

This research represents the first case of expression of all individual PT subunits in
5. typhimurium aroA and the subsequent simultaneous expression of all five PT
subunits in this bacterium. Previously, recombinant S 1 had been expressed in S .
typhimurium SL3261 and S. typhi Ty21a (Walker et a l , 1992). Another group has
recently expressed SI as a fusion protein using the amino or carboxyl terminus fused
to the tetanus toxin fragment C in S. typhi aroC aroD CVD908 (Barry et al., 1996).
All other PT subunits apart from SI have not previously been expressed in attenuated
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Salmonella spp.

In m ost instances, those constructs which expressed PT subunits in E. coli strains
were also expressed in S. typhimurium aroA. Incomplete processing of subunits
may have resulted from overloading of the bacterial secretion pathway. The decrease
in number of bacteria recovered in the invasion assay for strains containing pDP16
may be the result of blockage of the bacterial secretion pathway, and a consequential
build up of unprocessed subunits in the cytoplasm. Such changes may result in a
reduction in the secretion of proteins involved in eukaryote cell invasion, a decrease
in bacterial growth, or both.

Mice orally immunised with SL7207 (pDP16) showed a significant serum antibody
response directed against the immunodominant SI subunit, whereas SL3261
(pDP16) failed to stimulate a detectable antibody response. Lack of reactivity to the
B-oligomer may not necessarily mean that antibodies are not present in the sera; such
antibodies may react only with conformational epitopes present of the native toxin.
Differences in the immune response of these two strains may reflect differences in
the attenuation of SL3261 and SL7207. Using a single oral dose of SL7207 (pDP16)
induced at 39.5°C, the immune response engendered was not protective in an
intracerebral challenge assay, possibly reflecting the lack of protective B-cell epitopes
which are present on the native toxin (Burnette et al., 1992b). In a previous study,
the SI subunit expressed in S. typhimurium SL3261 was found to engender both a
lung and systemic immune response following oral immunisation (Walker et al.,
1992), however, the protective efficacy of this oral vaccine was not investigated. The
growth and in vitro invasiveness of SL3261 (pDP16) in comparison with SL3261
expressing only the S 1 subunit may account for the observed differences in the
immune response; SL3261 expressing the SI subunit was found to be as invasive as
plasmid-less controls (Walker et a l, 1992). In another recent study, mice immunised
orally with S. typhi aroC aroD CVD908 producing a SI-tetanus toxin fragment C
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fusion protein did not elicit consistent serum or lung antibody responses (Barry et
al., 1996). The lack of an antibody response in this study may have been due to
strain growth, solubility of the foreign antigen or the masking of epitopes by the
fusion protein which may have blocked immune responses against S I. The
protective efficacy of this vaccine preparation was also not determined.

To improve processing of PT subunits in Salmonella spp. similar strategies that are
proposed for improvement of processing in E. coli could be used. The signal peptide
1 from S. typhimurium has been cloned and characterised at the molecular level (Van
Diji et aL, 1992). Over-expression of this signal peptidase or that from E. coli may
improve the processing of PT subunits. The problems of vaccine strain viability and
immunogenicity encountered in this study may eventually be overcome using various
strategies. For instance, strain growth may be improved by the use of in vivoactivated promoters that restrict expression of the heterologous antigen until the
bacterial vector reaches the intestinal mucosa or has invaded eukaryote host cells.
Several such promoter systems are being developed for this purpose (Dougan, 1994;
Staendner et al., 1995). The anaerobically inducible nirB promoter has previously
been used to immunise mice with a S. typhimurium aroA aroD vaccine strain
expressing the fragment C of tetanus toxin. This construct was found to be stably
inherited by bacteria growing or persisting in the tissues of immunised mice, in
contrast to a construct which utilised the tac promoter. The nirB construct was found
to generate antibody responses in these mice following boost, but the mice were only
partially protected against tetanus toxin challenge (Chatfield et al., 1992). This
prom oter has also been used to express the P69 antigen of B. pertussis to levels of
up to 30% of the total cell volume (Oxer et al., 1991). The improvement of strain
growth using in vivo-activated promoters may also improve the subsequent immune
response engendered against PT by strains containing the synthetic PT operon. In
another study, genes encoding two E. coli envelope proteins, the outer membrane
protein LamB and the periplasmic protein MalE, were placed under the control of the
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pnir promoter on pBR322 plasmid derivatives, and both proteins were expressed at
high levels during anaerobic growth. This promoter was found to direct a four fold
increase in the level of MalE expression relative to the level reached by the tac
prom oter construct. A MalE-HIV 1 hybrid protein was also over-expressed under
pnir control, without apparent degradation of the hybrid protein. When this construct
was expressed in S. typhimurium aroA SL3261, the plasmids carrying the foreign
genes were found to be stable in vitro and in vivo (Newton et al., 1995). In another
study the htrA prom oter was used to express LacZ in S. typhimurium BRD 915
(SL1344 htrA), and expression significantly increased when S. typhimurium entered
eukaryotic cells, including m acrophages (Everest et al., 1995). Secondly,
incorporation of the synthetic PT operon into the chromosome may improve the
stability of antigen expression in vivo. In this approach, the expression of the foreign
protein is reduced since the genes are only present in one copy, however, it is still
possible to obtain a protective immune response (Dougan, 1994). Such a system that
uses non-antibiotic resistant mini-transposons which allow the stable integration of
foreign genes into the bacterial chromosome has been developed (Herrero et al.,
1990). In a similar approach, a defective transposable element which stably inserts
into the bacterial chrom osome has been used to express foreign genes in S.
typhim urium aroA, and has been found to generate a cytotoxic T-cell response
against the foreign antigen in mice (Flynn et al., 1990). Such strategies that involve
the integration of foreign genes into the bacterial chromosome may be useful for the
stable expression of PT genes. Finally, an attenuated strain of S. typhimurium
expressing the cytokine interleukin-6 has been developed (Dunstan et al., 1996).
Such studies may lead to the development of attenuated bacterial vectors co
expressing a repertoire of cytokines which results in an improved immune response
against heterologous antigens.

In this study, S. typhimurium aroA strains simultaneously expressing the five PT
subunits have been characterised. Significant antibody responses in the sera of
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vaccinated mice were detected following oral immunisation with S. typhimurium
SL7207 (pDP16) induced at 39.5°C. No protection was observed in vaccinated mice
follow ing intracerebral challenge with this vaccine. The findings of this study
indicate that expression of PT subunits was detrimental to the host cell, which
displayed decreased invasion and growth characteristics which is, probably in part,
responsible for the low antibody response detected in mice immunised with this
vaccine preparation. Although this study was limited to assessment of antibody
responses following oral immunisation, it is recognised that cell mediated immunity
does play a role in protection against disease following immunisation or infection
with B. pertussis (Zepp et al., 1996). Such studies would need to be conducted in
future trials. Despite these difficulties, the use of live oral vaccines expressing B.
pertussis antigens remains an attractive alternative to parenterally administered
pertussis vaccines, in stimulating a local immune response at the site of infection.
Additionally this delivery system would be cost effective to produce and easily
administered, thus being highly suitable for Third World vaccination programs.
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5.

CONCLUSION

Pertussis toxin is the major virulence factor of B. pertussis. The inability to express
PT in E. coli using the wild-type promoter and ribosomal binding site has hampered
the development of new generation pertussis vaccines. A major aim of pertussis
vaccine research is the over-production of PT in a background devoid of other
compounds present in B. pertussis that may contribute to the side effects commonly
observed following whole-cell pertussis vaccination. Additionally, the ability to
express this antigen in attenuated Salmonella spp. would permit the development of
orally administered pertussis vaccines. Such vaccines are considered superior to
parenterally administered vaccines currently in use, due to their ability to invoke a
mucosal IgA response in the lungs, the site of colonisation.

In this research the five PT genes have been individually and simultaneously
expressed in E. coli. The results of this study indicate expression and signal peptide
processing of the PT subunits was variable. In E. coli CAG629 S2, S3, S4 and S5
were partially processed, whilst S5 was completely processed in this strain. An
operon capable of simultaneously expressing the five PT subunits was subsequently
constructed using a novel cloning strategy which enabled different combinations of
the PT genes to be cloned. In E. coli KS476 (pDP16) SI and S4 were partially
processed, S2 and S3 were unprocessed and S5 was completely processed.
Subcellular fractionation studies detected SI and S3 in periplasmic extracts, whilst,
S2, S4 and S5 were not detected in periplasmic extracts. The majority of all PT
subunit proteins were found to be localised to the cytoplasm. E. coli K S 476
expressing the five PT subunit genes showed a decrease in viability following
temperature induction at 42°C.

Using attenuated aroA derivatives of S. typhimurium, SL3261 and SL7207, the five
PT subunits have been both individually and simultaneously expressed. As is the
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case with E. coli, signal peptide processing was variable. In SL7207 (pDP16)
expressing the five PT subunits SI was com pletely processed, S2, S3 and S4
rem ained unprocessed whilst S5 was completely processed. S typhimurium SL7207
(pDP16) displayed reduced viability and in vitro invasiveness for eukaryote cells
com pared to plasm id-less or vector-only strains. W hen this vaccine strain was used
to orally im m unise mice a significant anti-S 1 response was invoked, as detected by
w estern blot analysis. The protectiveness of this vaccine strain was assessed in a
m ouse intracerebral challenge assay; results obtained indicated that this strain was
non-protective following challenge with live B. pertussis.

Expression o f a recom binant PT operon in E. coli and S. typhimurium represents a
significant achievem ent in the developm ent o f new generation w hooping cough
vaccines. The problem s encountered in this research can be addressed with the
developm ent o f new strategies aimed at optimising PT processing and expression in
E. coli an d Salm onella sp p ., thus potentially im proving strain viability and
immunogenicity. Such strategies that will be investigated in future work include the
use o f different leader peptides such as B-lactamase that direct the secretion of foreign
gene products. A dditionally, chaperone proteins which function in assisting the
processing and secretion o f proteins into the periplasm will be co-expressed in
strains containing pD P16. In order to im prove the im m unogenicity o f S.
typhimurium spp. harbouring pDP16, the use of in vivo promoters such as nirB, that
are activated following bacterial invasion of eukaryote cells will be utilised, such
prom oters have shown promising results in other studies.
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7.

APPENDICES

A.

MEDIA

i.

2YT Agar
2YT agar contained tryptone, 16 g/1; yeast extract, 10 g/1; sodium chloride, 5
gA; Agar, 15 g/1.

ii.

X-gal Agar
X-gal agar was prepared by adding 2 ml of a 2% X-gal in DMF solution and
0.4 ml of a 100 mM solution of IPTG to 11 of sterile, cooled 2YT agar.

iii.

BG Agar
BG agar contained Bordet Gengou agar base, 30 g/1; glycerol, 10 ml/1; 150
ml/1 defibrinated horse blood was added to the cooled agar base.

iv .

XP Agar
XP agar was prepared by the adding 5 ml of a 10 mg/ml XP in DMF solution
and 0.4 ml of a 100 mM solution of IPTG to 11 of sterile, cooled 2YT agar.

v.

Z Agar
Z agar contained glucose, 1.0 g/1; calcium chloride, 0.367 gA; sodium

chloride, 2.5 gA; tryptone, 10.0 gA; yeast extract, 5.0 gA, agar, 15.0 gA.

vi.

LB Broth
LB broth was used to inoculate all bacterial cultures, it contained tryptone, 10
gA; yeast extract, 5 gA; sodium chloride, 10 gA.
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vii.

SOC Media
SOC media was used in conjunction with the TA Cloning™ Kit. It contained
tryptone, 2%; yeast extract, 0.5%; sodium chloride, 10 mM; potassium
chloride, 2.5 mM. A 2 M stock of Mg2+, comprised of 1 M MgCl2 and 1 M
MgSC>4 was filter sterilized, along with a 2 M glucose stock. These were
added to the sterile media just prior to use, and the media was then filter
sterilised.

B.

BUFFERS

i.

TAE Buffer
TAE buffer (xlO) for agarose gel electrophoresis contained Tris-base, 48.44
g/1; sodium acetate, 27.22 g/1; EDTA, 7.44 g/1; pH 8.0.

ii.

TBE Buffer
TBE buffer (x 10) for DNA sequencing contained Tris-base, 162 g/1; boric
acid, 27.5 g/1; EDTA, 9.5 g/1. The pH of this solution is approximately pH 8
and was not adjusted.

iii.

SDS-PAGE Running Buffer
SDS-PAGE Running Buffer (x 8) contained Tris-base, 15 g/1; glycine, 72 g/1;
SDS, 5 g/1. The pH of this solution is approximately pH 8.3 and was not
adjusted.

iv.

Western Transfer Buffer I
Western transfer buffer used for nitrocellulose filters contained Tris-base, 5.8
g/1; glycine, 2.9 g/1; SDS, 3.75 g/1; methanol, 20%.
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v.

Western Transfer Buffer II
Western transfer buffer for PVDF contained Tris-base, 3.1 g/1; glycine, 14.4
gA; methanol 20%.

vi.

Phosphate Buffered Saline
Phosphate buffered saline contained NaCl, 8.0 g/1; KC1, 0.2 g/1; Na2HPC>4,
1.15 g/1; KH2P0 4 , 0.2 g/1. The pH of this solution is approximately pH 7.4
and was not adjusted.

vii.

Fractionation Buffer
Fractionation Buffer contained sucrose, 250 g/1; EDTA, 1 mM; Tris-HCl, 10
mM; pH 8.0.

viii.

T4 DNA Ligase Buffer x 10 (Boehringer Mannheim)
The ligation buffer contained Tris-HCl, 660 mmol/1; MgCl2, 50 mmol; DTT,
10 mmolA; ATP, 10 mmolA; pH 7.5 (at 20°C).

ix .

Dephosphorylation Buffer x 10 (Boehringer Mannheim)
The dephosphorylation buffer contained Tris-HCl, 0.5 molA; EDTA, 1
mmolA; pH 8.5 (at 20°C).

x.

T7 Polymerase Dilution Buffer (Pharmacia)
The T7 polymerase dilution buffer contained Tris-HCl, 20 mM (pH 7.5);
DTT, 5 mM; BSA, 100 pg/ml; glycerol, 5%.

x i.

Annealing Buffer (Pharmacia)
The annealing buffer for DNA sequencing contained Tris-HCl (pH 7.6), 1 M;
MgCl2, 100 mM; D IT , 160 mM.
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xii.

PCR Reaction Buffer x 10 (Boehringer Mannheim)
The PCR buffer contained Tris-HCl, 100 mM; MgCl2, 15 mM; KC1, 500
mM; pH 8.3 ( at 20°C).

xiii.

Labelling Mix-dATP (Pharmacia)
The d-ATP labelling mix contained dCTP, dGTP, dTTP, 1.375 |iM of each;
NaCl, 333.5 mM.

xiv.

Phosphate-Citrate Buffer
The phosphate citrate buffer was prepared by mixing 25.7 ml of 0.2 M NaPC>4
with 24.3 ml of 0.1 M citric acid. pH to 5.0.

C.

i.

ACRYLAMIDE SOLUTIONS

SDS-PAGE Stacking Gel
SDS-PAGE stacking gel (4%) contained 1.1 ml of a 35% acrylamide/0.8%bisacrylamide solution; Tris-HCl 0.5 M (pH 6.8), 2.5 ml; 10% SDS, 0.1 ml;
gdH20 , 6.3 ml; ammonium persulfate 10%, 0.05 ml; TEMED, 0.05 ml.

ii.

SDS-PAGE Resolving Gel
SDS-PAGE resolving gel (15%) contained 6.3 ml of a 35% acrylamide/0.8%
bis-acrylamide solution; Tris-HCl 1.5 M (pH 8.8), 2.5 ml; 10% SDS, 0.1 ml;
gdH20 , 3.4 ml; ammonium persulfate 10%, 0.05 ml; TEMED, 0.05 ml.

iii.

Sequencing Gel
Sequencing Gel (5%) contained 5 ml of a 50% 19:1 acrylamide/bis-acrylamide
solution; TBE (x 10), 5 ml; urea, 23 g; ammonium persulfate 10%, 0.25 ml;
TEMED, 0.05 ml; and was made up to 50 ml with gdH20.
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D.

LOADING DYES

i.

Agarose Loading Dye
Agarose gel electrophoresis loading dye consisted of Ficoll 400,15% ;
bromophenol blue, 0.25%.

ii.

PAGE Sample Buffer
PAGE sample buffer contained Tris-HCl (pH 6.8), 60 mM; SDS, 1%; Bmercaptoethanol, 10%; glycerol, 10%; bromophenol blue, 0.01%; pH 6.8.

iii.

Sequencing Stop Buffer (Pharmacia)
Sequencing stop solution contained bromophenol blue, 0.3%; xylene cyanol
FF, 0.3%; 10 mM EDTA (pH 7.5); deionised formamide, 97.5%.

E.

BUFFERS FOR PL A SM ID E X T R A C T IO N

i.

Buffer PI (Qiagen)
Buffer PI contained RNase A, 100 mg/1; Tris-HCl, 6.06 g/1; EDTA, 3.72 g/1;
pH 8.0, store at 4°C.

ii.

Buffer P2 (Qiagen)
Buffer P2 contained NaOH, 8.0 g/1;20% SDS, 50 mlA.

iii.

Buffer P3 (Qiagen)
Buffer P3 contained potassium acetate, 294.45 g/1.
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iv .

Buffer QBT (Qiagen)
Buffer QBT contained NaCl 43.83 g/1; MOPS, 10.46 g/1; ethanol, 15 ml;
Triton X-100, 0.15%; pH 7.0.

v.

Buffer QC (Qiagen)
Buffer QC contained NaCl 1 M, 43.83 g/1; MOPS, 10.46 g/1; ethanol, 15%;
pH 7.0.

v i.

Buffer QF (Qiagen)
Buffer QF contained NaCl, 73.05 g/1; Tris-HCl, 6.06 g/1; ethanol, 15%; pH
8.5.

vii.

Alkaline Sucrose Solution
Alkaline sucrose solution contained sucrose, 150 g/1; EDTA, 18.5 g/1; Trisbase, 6.0 g/1; pH 8.5.

viii.

Alkaline Triton Solution
Alkaline triton solution contained Triton X-100, 1 ml/1; EDTA, 18.5 g/1; Trisbase, 6.0 g/1; pH 8.5.

G.

SOLUTIONS

i.

Coomassie Blue Stain
The Commassie blue stain for protein gels contained Commassie brillant blue
R250, 0.1%; methanol, 50%; acetic acid, 10%.

ii.

Destain Solution
The destain solution for protein gels contained methanol, 40%; acetic acid

10% .
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iii.

ELISA Substrate Solution
The ELISA substrate solution contained 6 mg/ml tetramethylbenzidine
dihydrochloride diluted in 0.1 M phosphate-citrate buffer (B.xiv). 2 |il of
H 2O2/IO ml of substrate solution was added immediately prior to use.

iv .

Fixing Solution
The fixing solution for sequencing gels contained methanol, 10%; acetic acid,
10 %.

v.

Developer Solution (Kodak)
The developer solution for X-ray film contained developer, 25%.

v i.

Fixing Solution (Kodak)
The fixing solution for X-ray film contained fixer 25%.

vii.

Western Blot Colour Development Solution
The colour development solution consisted of two separate solutions combined
immediately prior to use. Solution A contained gdH20, 30 ml; H2O2, 20 pi.
Solution B contained 4-chloro-l-napthol, 30 mg; methanol, 10 ml.

H.

PRIMER MELTING TEMPERATURE
Melting temperature is that temperature at which 50% of the primer no longer
hybridises to the template DNA. It depends on the specificity of the primer and
the GC content.

less than 20 nucleotides:
greater than 20 nucleotides

2(AT) + 4(GC)
% GC( 0.41) + 69.3 - 6£0
#bp
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PCR annealing temperatures were taken as being 5°C below the true Tm of the
primers.
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I.

T H E STA N D A RD G E N E T IC CO D E
U

u

c

A

G

A

C

u u u Phe
u u c Phe

ucu
ucc

UUA Leu
UU G Leu

G

UAU Tyr
UAC Tyr
UAA Stop
UAG Stop

UGU
UGC
UGA
UGG

Cys
Cys
Stop
Trp

U

UCA
UCG

Ser
Ser
Ser
Ser

CUU

Leu
c u e Leu
CUA Leu
CUG Leu

CCU
CCC
CCA
CCG

Pro
Pro
Pro
Pro

CAU
CAC
CAA
CAG

His
His
Gin
Gin

CGU
CGC
CGA
CGG

Arg
Arg
Arg
Arg

U
C
A
G

AUU lie
AUC He
AUA ne
AUGtMet

ACU
ACC
ACA
ACG

Thr
Thr
Thr
Thr

AAU
AAC
AAA
AAG

Asn
Asn
Lys
Lys

AGU Ser
AGC Ser
AGA Arg
AGG Arg

U
C
A
G

Val
Val
Val
Val

GCU
GCC
GCA
GCG

Ala
Ala
Ala
Ala

GAU
GAC
GAA
GAG

Asp
Asp
Glu
Glu

GGU
GGC
GGA
GGG

Gly
Gly
Gly
Gly

U
C
A
G

GUU
GUC
GUA
GUG

c
A
G

tAUG is part o f the initiation codon as well as an initial methionine
SYMBOLS FOR AMINO ACIDS
A
B
C
D
E
F
G
H
I
K
L
M
N
P
Q
R
S
T
V

w
Y
Z

Ala
Asx
Cys
Asp
Glu
Phe
Gly
His

ne
Lys
Leu
Met
Asn
Pro
Gin
Arg
Ser
Thr
Val
Trp
Tyr
Glx

Alanine
Asparagine or aspartic acid
Cysteine
Aspartic Acid
Glutamic Acid
Phenylalanine
Glycine
Histidine
Isoleucine
Lysine
Leucine
Methionine
Asparagine
Proline
Glutamine
Arginine
Serine
Threonine
Valine
Tryptophan
Tyrosine
Glutamine or glutamic acid
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